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Abstract  
Key regulatory events take place at very early stages of human embryonic 
stem cell (hESC) differentiation to accommodate their ability to differentiate into 
different lineages; this work examines two separate regulatory events.  
To investigate precise mechanisms that link alterations in the cell cycle 
and early differentiation, we examined the initial stages of mesendodermal 
lineage commitment and observed a cell cycle pause that occurred concurrently 
with an increase in genes that regulate the G2/M transition, including WEE1. 
Inhibition of WEE1 prevented the G2 pause. Directed differentiation of hESCs 
revealed that cells paused during commitment to the endo- and mesodermal, but 
not ectodermal, lineages. Functionally, WEE1 inhibition during meso- and 
endodermal differentiation selectively decreased expression of definitive 
endodermal markers SOX17 and FOXA2. These findings reveal a novel G2 cell 
cycle pause required for endodermal differentiation. 
A role for phenotypic transcription factors in very early differentiation is 
unknown.  From a screen of candidate factors during early mesendodermal 
differentiation, we found that RUNX1 is selectively and transiently up-regulated. 
Transcriptome and functional analyses upon RUNX1 depletion established a role 
for RUNX1 in promoting cell motility. In parallel, we discovered a loss of 
repression for several epithelial genes, indicating that RUNX1 knockdown 
impaired an epithelial to mesenchymal transition during differentiation. Cell 
biological and biochemical approaches revealed that RUNX1 depletion 
vi  
compromised TGFβ2 signaling. Both the decrease in motility and deregulated 
epithelial marker expression upon RUNX1 depletion were rescued by 
reintroduction of TGFβ2, but not TGFβ1. These findings identify novel roles for 
RUNX1-TGFβ2 signaling in mesendodermal lineage commitment. 
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CHAPTER I. Introduction 
 
1.1 Human embryonic stem cells 
How can a full human being originate from a single zygotic cell? This central 
question, while simple, leads to a host of more detailed and complex questions. 
Since early development takes place inside a female human being, and is 
therefore inaccessible, it makes studying the early mechanistic details of the 
process very difficult. Thus, human embryonic stem cells (hESCs) were isolated 
from the inner cell mass of a blastocyst stage embryo, which forms within five 
days of fertilization of an oocyte (Reubinoff et al., 2000; Thomson et al., 1998), 
providing a model system for the study of early human development. 
Human embryonic stems have unique properties, which include an unlimited 
replicative potential and the capability to differentiate into any somatic cell type, 
termed pluripotency (Thomson et al., 1998). The unlimited replicative potential of 
hESCs is maintained through high levels of expression of telomerase, which 
ensures retention of the telomere ends on chromosomes with each cell division 
and prevents the cells from reaching the Hayflick limit and undergoing 
senescence (Amit et al., 2000). The expression of telomerase is part of a 
regulatory network that maintains the self-renewal and pluripotency of hESCs. 
This regulatory network contains both auto-regulatory and feed-forward loops, 
and is dominated by three transcription factors, OCT4 (Niwa et al., 2000), 
NANOG (Chambers et al., 2003), and SOX2 (Avilion et al., 2003; Fong et al., 
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2008), which are essential for maintenance of pluripotency and self-renewal 
(Boyer et al., 2005). 
 In order to be maintained in culture, hESC are grown on either a feeder 
layer (typically mouse embryonic fibroblasts) or under feeder-free conditions.  
When hESCs are kept under feeder-free conditions, as they were for the work in 
this dissertation, they are grown on a matrix composed of one of several 
substrates (including Matrigel, vitronection, laminin, fibronectin, or collagen IV 
among others) (Xu et al., 2001) with media containing specific growth factors that 
promote pluripotency. The two most important growth factors are bFGF and 
TGFβ1/Nodal, which are thought to suppress BMP signaling that induces 
differentiation (Xu et al., 2005), while TGFβ1 also specifically increases NANOG 
expression (Chen et al., 2011; Xu et al., 2008). 
1.2 Unique Cell Cycle Regulation in hESCs 
Maintenance of human embryonic stem cell pluripotency is tightly linked to 
cell cycle control (Kapinas et al., 2013; White and Dalton, 2005). Human 
embryonic stem cells have a unique cell cycle with a G1 phase shorter than that 
of somatic cells (~3h vs. ~10h) (Becker et al., 2006). Lengthening of the G1 
phase has been linked to differentiation and loss of pluripotency (Calder et al., 
2013; Filipczyk et al., 2007). Recent studies have shown that onset of 
differentiation likely occurs in the G1 phase, with endo- and mesodermal 
differentiation initiating in early G1 and the neuroectodermal lineage arising 
during late G1 (Pauklin and Vallier, 2013; Sela et al., 2012). The G2/M/S phases 
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of the hESC cell cycle are minimally responsive to differentiation cues (Pauklin 
and Vallier, 2013).  
Regulation of the cell cycle during the differentiation process has been 
primarily attributed to known negative regulators of proliferation in somatic cells, 
including p21 and p27 (Calder et al., 2013; Egozi et al., 2007; Zhu et al., 2014). 
The levels of p21 and p27 remain low in pluripotent hESCs, and increase upon 
differentiation. A recent study found that to maintain pluripotency the expression 
of p21 and p27 must be repressed, as elevated levels of p21 and p27 resulted in 
an increased G1 phase occupancy (Menchón et al., 2011; Zhu et al., 2014). 
Additionally, p27 can directly repress SOX2 during differentiation (Li et al., 2012). 
While a correlation between the lengthening of the cell cycle and initiation of 
hESC differentiation has been established, mechanisms that coordinate changes 
in the cell cycle and differentiation are not fully understood. 
1.3 Regulation of the G2/M Transition of the Cell Cycle 
Since much of the focus on cell cycle regulation in hESCs has been on the 
role of the G1 phase, and the G1/S transition, this allows for potential novel 
discoveries in the other phases of the cell cycle. The G2 phase of the cell cycle 
begins at the completion of DNA replication and includes a period of rapid protein 
production and cell growth that concludes upon initiation of prophase of mitosis. 
The events that modulate the transition from G2 to mitosis form a checkpoint that 
prevents premature mitosis in cells with defects such as incomplete DNA 
replication or DNA damage that needs more time to be corrected (O’Connell and 
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Cimprich, 2005; Zhou and Elledge, 2000). Progress through the mammalian cell 
cycle is mediated by the sequential activation of cyclin dependent kinases (cdks) 
(Pines, 1995). The activation of the cdks is regulated by both stage specific cyclin 
binding and phosphorylation events.  
A key regulatory event in the activation of cdks and the transition from G2 to 
mitosis is the formation of a complex between CDK1 and one of the five isoforms 
of Cyclin B (Nigg, 1995). This complex was originally identified as the maturation-
promoting factor or M phase-promoting factor (MPF) in meiotic frog eggs, since it 
was capable of inducing mitosis in immature G2 phase oocytes (Masui and 
Markert, 1971). While in humans it is generally thought that the levels of CDK1 
remain constant throughout the cell cycle, the levels of Cyclin B1 mRNA and 
protein change with cell cycle progression (Smits and Medema, 2001). The 
transcription from the Cyclin B1 promoter increases after S phase and decreases 
during the beginning of G1, and Cyclin B1 protein is degraded during the 
metaphase-anaphase transition during mitosis (Piaggio et al., 1995; Pines and 
Hunter, 1989).  
During interphase Cyclin B interacts with importin β, is imported into the 
nucleus, and then is swiftly shuttled out of the nucleus due to an N-terminal 
nuclear export signal (Hagting et al., 1998; Takizawa et al., 1999; Toyoshima et 
al., 1998). Once the MPF complex levels in the cytoplasm increase, due to an 
increase in total Cyclin B, the Cyclin B portion of the complex is phosphorylated 
near the nuclear export signal on residues S133 and S147, creating a nuclear 
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localization signal, which increases the rate of nuclear import beyond what would 
be caused by simply blocking the nuclear export signal (Hagting et al., 1999; 
Toyoshima-Morimoto et al., 2001).  
In addition to the regulation of the formation and localization of the MPF, 
there are multiple phosphorylation events on CDK1 that control the transition 
from G2 to mitosis. An activating phosphorylation of CDK1 is placed on T161 in 
the T-loop by the Cyclin Activating Kinase (CAK), which is a heterotrimeric 
complex composed of Cdk7, Cyclin H, and MAT1 (Tassan, 1994). This activating 
phosphorylation is opposed by a set of inhibitory phosphorylations. The WEE1 
and MYT1 kinases are responsible for placing these inhibitory phosphorylations 
on CDK1 in the MPF complex. WEE1 primarily phosphorylates Y15 of CDK1, 
while the MYT1 kinase can phosphorylate either T14 or Y15 (Booher et al., 1997; 
Liu et al., 1997; Parker and Piwnica-Worms, 1992). Phosphorylation of Y15 on 
CDK1 interferes with phosphate transfer to a bound substrate, while the 
phosphorylation of T14 interferes with ATP binding (Atherton-Fessler et al., 1993; 
Endicott et al., 1994). Cyclin B binding mediates these inhibitory 
phosphorylations on CDK1 (Meijer et al., 1991).  
Once CDK1 is bound to Cyclin B and phosphorylated by CAK and 
WEE1/MYT1, it is primed and ready to be activated through the 
dephosphorylation of T14 and Y15, which triggers the initiation of mitosis. 
Dephosphorylation of T14 and Y15 is performed by the dual specificity 
phosphatase CDC25, which can dephosphorylate phospho-tyrosine as well as 
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phospho-threonine residues (Gautier et al., 1991; Kumagai and Dunphy, 1991; 
Strausfeld et al., 1991). Conversely, the MPF complex can then phosphorylate 
WEE1 and CDC25, which inhibits WEE1 and further activates CDC25, which can 
then further dephosphorylate CDK1 on T14 and Y15 (Hoffmann et al., 1993; 
Mueller et al., 1995). This amplifies the signal and contributes to a burst of MPF 
activity, which initiates mitosis through the phosphorylation of downstream 
targets. Importantly, these targets include nuclear lamins that cause nuclear-
envelope breakdown, microtubule-associated proteins that promote assembly of 
the mitotic spindle assembly, and condensin subunits that are responsible for 
chromosome condensation (Heald and McKeon, 1990; Kimura et al., 1998; 
Miake-Lye et al., 1983; Tombes et al., 1991). 
Interestingly, in mice, of the CDKs, only CDK1 is essential for survival 
(lethality by E1.5)(Santamaría et al., 2007). Of the cyclins, only disruption of 
cyclin A2 and cyclin B1, which have roles in the S/G2/M phases, results in 
embryonic lethality early in development (E5.5 and before E10.5/not determined, 
respectively) (Brandeis et al., 1998; Gong and Ferrell, 2010; Gong et al., 2007; 
Murphy et al., 1997). Additionally, information regarding a role for WEE1 in 
mammalian development has been limited because there is a requirement for 
WEE1 prior to blastocyst formation in development that ends with embryonic 
lethality prior to E3.5 in WEE1-deficient mice due to apoptosis as a result of an 
accumulation of DNA damage (Tominaga et al., 2006). Together, these studies 
indicate the importance of the regulation of G2/M transition. 
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Figure 1.1. Overview of the Regulation of the G2/M Transition. 
 
1.4 Strategies for Differentiating hESCs 
A key property of hESCs is their ability to differentiate into cell types from 
all three germ layers. The most widely used method to differentiate hESCs 
involves formation of three-dimensional spheroids designated embryoid bodies 
(EBs), which can spontaneously differentiate into ectoderm, mesoderm and 
endoderm (Itskovitz-Eldor et al., 2000; Keller, 1995; Segev et al., 2004; Xu, 
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2002). There are also numerous studies using EB differentiation protocols that 
require several days to weeks that focus on creating defined cell types (D’Amour 
et al., 2005; Gerrard et al., 2005; Takasato et al., 2014). Typically, embryoid body 
formation requires long incubation periods to induce differentiation (minimum 4-
5d to form EB spheroids), providing a challenge to investigate mechanisms 
operative in the earliest stages of differentiation. This method of differentiation 
does have the advantage that the three-dimensional culture more closely 
recapitulates an environment that would be found in vivo, with signals and 
cellular interactions coming from all directions, than two-dimensional culture.  
Another common method of inducing differentiation is to co-culture hESCs 
with another cell line/type that will produce the cues to induce the hESCs to 
differentiate to the desired lineage (Mummery et al., 2003; Vodyanik et al., 2005). 
The issues that arise with this method of differentiation include removal of the co-
cultured cell line after the desired lineage is generated, and the possibility of 
transmission of a pathogen, activation of retroviruses, or induction of 
immunogenicity resulting from exposure of the hESCs to cells or products from 
non-human species.  The simplest method to induce differentiation is through a 
monolayer differentiation, which is used for the experiments in this dissertation, 
avoids the pitfalls of other methods of differentiation and allows for the study of 
early differentiation (D’Amour et al., 2005; Gerrard et al., 2005; Takasato et al., 
2014).  
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1.5 Mesendoderm 
 Studies in lower vertebrates (C.elegans, Xenopus, and zebrafish) have 
shown that mesoderm and endoderm arise from a bipotent progenitor population 
(Maduro et al., 2001; Rodaway and Patient, 2001) known as the mesendoderm. 
Several studies have shown that there is a bipotent mesendodermal population 
during mammalian development as well, though whether the population is 
composed of cells that are truly bipotent or if the population is composed of a mix 
of progenitors that are already committed to each lineage is still up for debate 
(Lickert et al., 2002; Tada, 2005). Both mouse embryonic stem cells (mESCs) 
and hESCs can differentiate into mesendoderm (Kubo et al., 2004; Mahmood 
and Aldahmash, 2015; Tada, 2005), which is marked by early gene expression 
patterns similar to that of primitive streak with high expression of the markers 
BRACHYURY, MIXL1, or GSC (Pereira et al., 2011), though the exact timing of 
expression varies based on the method of differentiation (S. A. Jackson et al., 
2010; Mahmood and Aldahmash, 2015; Tada, 2005). From mesendoderm, both 
mESCs and hESCs can then differentiate to definitive endoderm or mesoderm 
(D’Amour et al., 2005; Lam et al., 2014). The activation of canonical Wnt/β-
catenin signaling in hESCs induces mesoderm (Davidson et al., 2012), whereas 
Activin A has been shown to mimic nodal, inducing differentiation into anterior 
primitive streak/endoderm progenitors (Sulzbacher et al., 2009). 
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1.6 The RUNX Family  
While much is known about the maintenance of pluripotency (Boward et 
al., 2016; Boyer et al., 2005; Chambers et al., 2003; Huang et al., 2015; Kapinas 
et al., 2013), how differentiation signals regulate the dissolution of pluripotency 
and the establishment of phenotype is not well understood.  Studies in hESCs 
have shown that many genes responsible for early developmental events are 
poised for either activation or repression by epigenetic mechanisms (Bernstein et 
al., 2006; Grandy et al., 2015; Szutorisz and Dillon, 2005).  Once a differentiation 
signal has been introduced, early factors are expressed that prime the gene 
expression program of cells for lineage acquisition (Zaret and Carroll, 2011). One 
category of factors that has potential to regulate the gene expression program of 
differentiating cells is transcription factors. 
 The RUNX (Runt-related transcription factor) family of genes, which is also 
known as the acute myeloid leukemia (AML), core-binding factor (CBF) or 
polyoma enhancer-binding protein-2α (PEBP2α) family of genes, contains three 
members: RUNX1, RUNX2, and RUNX3 (Ito, 2004). Each of the RUNX family 
transcription factors has known roles in development (Chuang et al., 2013). 
RUNX1 is necessary for definitive hematopoiesis (Okuda et al., 1996), RUNX2 
for bone formation (Otto et al., 1997), and RUNX3 for gastrointestinal and 
nervous system development (Inoue et al., 2002; Levanon et al., 2002; Li et al., 
2002). All three of the family members are implicated in malignancies as either 
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tumor suppressors or oncogenes in a context specific manner (Blyth et al., 2005; 
Ito, 2004).  
 All RUNX genes are transcribed from two promoters, the distal P1 and the 
proximal P2 (Bangsow et al., 2001; Drissi et al., 2000; Fujiwara et al., 1999; 
Ghozi et al., 1996), and contain similar structural domains. Each family member 
contains a highly conserved 128 amino acid region in the N-terminal region 
known as the runt domain due to its homology to the Drosophila Runt protein 
(Kagoshima et al., 1993; Ogawa et al., 1993b). This runt homology domain 
(RHD) is responsible for mediating heterodimerization with the Core Binding 
Factor β (CBFβ) protein, which stabilizes the protein complex, and binding the 
RUNX family’s consensus DNA sequence PyGPyGGTPy, where Py stands for 
either pyrimidine base (cytosine or thymine) (Melnikova et al., 1993; Ogawa et 
al., 1993a). CBFβ alone does not bind DNA (Ogawa et al., 1993a). A nuclear 
targeting signaling (NLS) is found on the C-terminal end of the RHD, which is 
required for the nuclear localization of the RUNX proteins and allows for access 
to its DNA targets (Kanno et al., 1998). 
 The RUNX family also has conserved regions on the C-terminus. Each family 
member has a nuclear matrix targeting signal (NMTS) in addition to the NLS. The 
NMTS is an ~31-38 amino acid sequence that is responsible for the sub-nuclear 
localization of the RUNX proteins to distinct nuclear sites to facilitate gene 
regulation (Stein et al., 2009; Zeng et al., 1998, 1997). The C-terminus is also 
comprised of additional domains that mediate gene regulation such as an 
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activation and inhibitory domain, the PPxY (or PY) motif, and the VWRPY motif. 
The PY motif is a proline-rich peptide that interacts with proteins containing the 
WW domain such as YAP, whereas the VWRPY motif interacts with proteins 
containing tryptophan-aspartic acid repeats, like Groucho/TLE transcription 
corepressors (Aronson et al., 1997; Chuang et al., 2013; Ito, 2004; Javed et al., 
2000). 
1.7 RUNX1 in Development  
 Developmental hematopoiesis begins with primitive hematopoiesis, where a 
limited number of blood lineages (mostly large erythroblasts) that sustain early 
embryonic development are produced primarily from the yolk sac (Chen et al., 
2014). A second wave of blood development, termed definitive hematopoiesis, 
occurs intra-embryonically in the aorta-gonad-mesonephros. During this stage of 
development, hematopoietic stem cells (HSCs) are formed that have the ability to 
produce any of the hematopoietic lineages and having long term repopulation 
capacity (Chen et al., 2014). RUNX1 is required for definitive hematopoiesis, as 
no definitive HSCs are formed in the absence of RUNX1. When genetically 
deleted in mice, Runx1 loss causes embryonic lethality due to major defects in 
the formation of the fetal liver and hemorrhaging in the central nervous system 
(Okuda et al., 1996; Wang et al., 1996). RUNX1 appears to be mostly 
dispensable once HSCs are formed, however, loss of RUNX1 has some effects 
on differentiation toward specific hematopoietic lineages (Growney et al., 2005; 
Ichikawa et al., 2008, 2004). It is hypothesized that RUNX1 is required to alter 
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chromatin, through unfolding and modification of the epigenetic landscape, to 
allow early hematopoiesis (Hoogenkamp et al., 2009; Lichtinger et al., 2012). 
  The RUNX1 transcript is expressed as three major isoforms, two from a 
proximal (isoforms a and b) and one from a distal (isoform c) promoter (Ghozi et 
al., 1996; Ran et al., 2013; Sroczynska et al., 2009). A study looking at Runx1 
isoform expression in early mouse hematopoietic development found that 
primitive erythrocytes that are produced prior to definitive hematopoiesis express 
mainly proximal promoter derived isoforms (Bee et al., 2009). However, in 
definitive HSCs from the yolk sac or aorta-gonad-mesonephros, transcription 
occurs from both the distal and proximal promoters, with isoforms from each 
promoter having non-redundant functions (Bee et al., 2010). Once cells have 
migrated to the fetal liver to establish adult hematopoiesis, the distal promoter 
gradually becomes the main hematopoietic promoter (Bee et al., 2009).  
 Previous studies of hematopoietic differentiation of hESCs have found an 
increase in RUNX1c mRNA levels between 8 and 12 days of differentiation from 
embryoid bodies that correlates with the emergence of the definitive 
hematopoietic lineage marker CD34. Also, low RUNX1b mRNA levels were 
observed throughout differentiation (Challen and Goodell, 2010; Zambidis et al., 
2005). Of note, in undifferentiated hESCs, the RUNX1 proximal promoter that 
expresses the RUNX1b transcript is bivalently marked with H3K27me3 and 
H3K4me3, indicating that it is poised for expression, while the distal promoter is 
not (Figure 1.2) (Mikkelsen et al., 2007). This could indicate that RUNX1 
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transcription from the proximal promoter is more permissive early in development 
and may have a role that is not linked to emergence of HSCs. The role of RUNX1 
in differentiation at very early time points in either directed or undirected 
differentiation of hESCs has been minimally explored, which was a major 
objective of Chapter III. 
 
Figure 1.2. The RUNX1 promoter is bivalently marked in pluripotent hESCs. Tracks marking H3K4ME3 and H3K27ME3 across the RUNX1 gene in three different hESC lines (H1, H7, and H9). H1 and H7 data is taken from GEO datasets GSE51334 and GSE35583, respectively, while the H9 data is taken from data from different cell cycle stages pooled together from the GEO dataset GSE55502. The P1 or distal promoter is marked in purple, while the P2 or proximal promoter is marked in cyan. Both H3K4ME3 and H3K27ME3 markers are found at the P2 promoter in all three cell lines.  
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 Emerging evidence indicates that RUNX1 has roles in non-hematopoietic 
lineages (Osorio et al., 2008; Scheitz and Tumbar, 2013; Stifani et al., 2008). 
Multiple reports have detailed a role for RUNX1 in epithelial biology (Scheitz and 
Tumbar, 2013). Studies have shown that RUNX1 modulates developmental 
activation and proliferation of hair follicle stem cells and inner olfactory nerve 
layer olfactory ensheathing cells (Hoi et al., 2010; Lee et al., 2014; Murthy et al., 
2014; Osorio et al., 2011, 2008). RUNX1 is a key regulator of the differentiation 
of mammary epithelium stem cells from a state of ductal and lobular bipotency 
(Sokol et al., 2015). Additional roles have been shown in other mesodermal 
derivatives such as mesenchymal stem cells, myofibroblasts and skeletal 
progenitors (Kim et al., 2014; Lian et al., 2003). 
1.8 TGFβ signaling  
 TGFβ signaling is a major contributor to specification of the body plan during 
metazoan development as well as other cellular processes including proliferation, 
apoptosis, recognition, and differentiation (Kitisin et al., 2007; Wu and Hill, 2009). 
The TGFβ superfamily is comprised of the TGFβ ligands (1,2, and 3), bone 
morphogenetic proteins, activins, inhibins, and other cytokines, all of which 
contain monomers with six cysteine residues in a “knot” formation (Kitisin et al., 
2007; Sun and Davies, 1995). The TGFβ ligands are synthesized in a latent state 
with large N-terminal pro-domains, which are necessary for the proper folding 
and homodimerization of the C-terminal regions of the proteins (Gray and Mason, 
1990).  Before secretion, the pro-domains are cleaved from the C-terminal 
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portion of the protein intracellularly by Furin, however the pro-domains still 
remain non-covalently associated with the rest of the protein to maintain latency 
(Dubois et al., 1995). Another peptide, termed the latent transforming growth 
factor β binding protein (LTBP), forms disulfide bonds with the N-terminal end of 
the TGFβ pro-domain within fifteen minutes of synthesis and aids in secretion 
and targeting of latent TGFβ to sites within the extracellular matrix (Miyazono et 
al., 1991; Taipale et al., 1994). TGFβ can be activated by a variety of methods, 
including integrin, thrombospondin, matrix glycoprotein, and protease mediated 
activation, as well as by potentially by mechanisms yet to be discovered (Alcaraz 
et al., 2014; Annes, 2003; Giacomini et al., 2012). 
 Once TGFβ has been activated, the ligand can then initiate signaling by 
binding to and bringing together type I and type II receptor serine/threonine 
kinases on the surface of a cell (Wrana et al., 1992). This binding induces 
transphosphorylation of the type I receptor by the type II receptor constitutively 
active kinases. The type I receptor then phosphorylates a set of receptor-
activated SMADs (R-SMADs), which include SMAD1, 2, 3, 5, and 8, on C-
terminal serines that then form complexes with SMAD4. SMADS 2 and 3 are 
mostly activated by activin/nodal/TGFβ ligand bound type I receptors, whereas 
SMADSs 1, 5 and 8 are mostly activated by BMP bound type I receptors 
(Miyazawa et al., 2002). The R-SMAD/SMAD4 complexes translocate into the 
nucleus, where they regulate transcription of target genes by interacting with or 
binding to DNA-binding transcription factors, CREB-binding protein, p300 
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coactivators, or many other factors (Itoh et al., 2000; Massagué, 2000, 1998; Shi 
and Massagué, 2003).  
 Activation of R-SMADs by type I receptor kinases is inhibited by SMAD6 or 
SMAD7 as part of a negative feedback loop thought to function in signal 
termination (Itoh and ten Dijke, 2007; Schmierer and Hill, 2007). SMAD6 
competes with SMAD4 for binding to activated SMAD1, sequestering the 
activated SMAD1 in apparently inactive complex (Hata et al., 1998). SMAD7 
interaction with the type I receptors leads to the ubiquitination and degradation of 
these receptors (Ebisawa et al., 2001; Tajima et al., 2003).  
 TGFβ can activate RUNX genes at the transcriptional level and at the 
posttranscriptional level through activation or stabilization of RUNX proteins (Jin 
et al., 2004; Klunker et al., 2009; Miyazono et al., 2004). Additionally, RUNX1 
can physically interact with SMAD factors to form complexes together with 
SMAD4 that appear to be critical for efficient transcriptional activation of target 
genes (Hanai et al., 1999). This allows the possibility that there could be 
additional regulation or interaction between RUNX1 and the TGFβ pathway to 
discover. 
1.9 Epithelial Mesenchymal Transition in Development 
 An epithelial-mesenchymal transition (EMT) is a biologic process that allows 
an epithelial or epithelial-like cell to undergo a series of changes that allow 
acquisition of a mesenchymal phenotype, including an enhanced migratory 
capacity, invasiveness, elevated resistance to apoptosis, and increased 
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production of ECM components (Kalluri and Neilson, 2003; Kalluri and Weinberg, 
2009). Elizabeth Hay first described the concept of EMT over 40 years ago in 
1968 (Hay, 1968).  
 During EMT, epithelial cells lose their junctions and apical–basal polarity, 
reorganize their cytoskeleton, and lose the expression of markers of an epithelial 
phenotype like E-Cadherin (CDH1), Occludin, Claudins, and Cytokeratins, while 
gaining expression of mesenchymal markers like Vimentin, N-Cadherin, CD44, 
Fibronectin, Fibroblast Specific Protein 1 (FSP-1), and α-Smooth Muscle Actin 
(α-SMA) (Kalluri and Weinberg, 2009; Lamouille et al., 2014). E-cadherin loss is 
considered to be necessary, but not on its own sufficient to induce EMT, as 
mesenchymal trait acquisition is required. The mechanisms controlling the loss of 
E-Cadherin are the most studied in EMT regulation. The transcription factors 
SNAIL1, SNAIL2 (SLUG), ZEB1, ZEB2, and TWIST1 bind to the E-Cadherin 
promoter and represses transcription of this gene (Cano et al., 2000; Comijn et 
al., 2001; Eger et al., 2005; Hajra et al., 2002; Vesuna et al., 2008; Yang et al., 
2004). These EMT promoting transcription factors also have additional roles 
beyond repression of E-Cadherin. SNAIL1 also directly represses claudins and 
Occludin expression (Ikenouchi et al., 2003). Additionally, ZEB2 is able to 
regulate genes crucial to formation of tight junctions, desmosomes and gap 
junctions, such as P-Cadherin, Claudin 4, Tight junction protein 3 (ZO-3), 
Plakophilin 2, Desmoplakin, Connexin 26 (GJB2) and Connexin 31 (GJB3) 
(Vandewalle et al., 2005). The EMT inducing transcription factors are regulated 
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by a variety of signaling pathways (including TGFβ, Wnt, and FGF, among many 
others) that can work in a cooperative manner to orchestrate the EMT process 
(Gonzalez and Medici, 2014; Moustakas and Heldin, 2007).  
 The EMT process is divided into three main types, developmental, wound 
healing and fibrosis, and metastasis (Zeisberg and Neilson, 2009). Since this 
dissertation focuses on mechanisms involved on early lineage commitment, only 
the developmental variety of EMT will be discussed. The first noted post-
implantation example of EMT is during the formation of the early mesoderm and 
endoderm during gastrulation (Viebahn, 1995). A subset of cells from the 
epiblast/primitive ectoderm, which arose from the inner cell mass of the embryo, 
moves to the embryo’s midline to form the primitive streak along the anterior-
posterior axis. These cells undergo EMT and move inward to generate 
mesoderm and endoderm, while those remaining in the epiblast become 
ectoderm (Acloque et al., 2009). Further waves of EMT occur as development 
progresses, including the formation of the neural crest, cardiac valve, and the 
secondary palate (Duband et al., 1995; Yang and Weinberg, 2008). Several 
studies have shown that early developmental EMT events can be recapitulated 
during hESCs differentiation, specifically in regard to mesendodermal lineages 
(D’Amour et al., 2005; Eastham et al., 2007; Evseenko, 2010). 
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CHAPTER II. Lineage-Specific Early Differentiation of Human Embryonic Stem Cells Requires a G2 Cell Cycle Pause 
 
2.1 Introduction 
In this chapter, we investigated the link between cell cycle progression 
and early differentiation using monolayer hESC cultures. Unexpectedly, we 
observed a cell cycle pause in G2 during differentiation to several lineages that 
was regulated by WEE1. When WEE1 was inhibited, this cell cycle pause was 
disrupted, and lineage determinant gene expression was compromised. These 
findings provide a novel mechanistic dimension to functional relationships 
between control of proliferation and induction of phenotype. 
A large portion of this chapter comes from the published work: 
VanOudenhove JJ, Grandy RA, Ghule PN, del Rio R, Lian JB, Stein JL, Zaidi SK, Stein, GS. Lineage-Specific Early Differentiation of Human Embryonic Stem Cells Requires a G2 Cell Cycle Pause. Stem Cells. [Epub ahead of print]. PMID: 26946228  
All data and figures in this chapter were obtained/created by Jennifer J. 
VanOudenhove, with the exception of the raw FACS data was collected on the 
LSRII and the ModFit analysis of FACS data was performed by Dr. Roxanna del 
Rio in the Flow Cytometry and Cell Sorting Facility at the University of Vermont.  
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2.2 Materials and Methods 
2.2.1 Stem Cell Culture 
The female H9 (WA09) line and the male H1 (WA01) line of hESCs were 
maintained on Matrigel using WiCell Research Institute (Madison, WI) Standard 
Operating Procedures (SOP-SH-002 or SOP-SH-004) for Feeder Independent 
Growth using pluripotency supporting mTeSR1 medium (Stem Cell 
Technologies, Vancouver, BC, Canada) or E8 medium (Life Technologies, 
Carlsbad, CA) respectively, and the EDTA passaging method, using a shorter (5 
min) exposure to EDTA. For fetal bovine serum (FBS)-induced mesendodermal 
differentiation, undifferentiated monolayer hESC cultures were switched from 
mTeSR1 to differentiation medium containing KNOCKOUT™ Dulbecco’s 
modified Eagle’s medium (DMEM), 20% heat inactivated, defined FBS, 1mM L-
glutamine with 1% v/v 2-mercaptoethanol, and 0.1 mM nonessential amino acids. 
For retinoic acid (RA)-induced ectodermal differentiation, undifferentiated 
monolayer hESC cultures were switched from E8 to differentiation medium with 
E6 basal medium (E8 medium without the pluripotency supporting growth factors: 
TGFβ1 and bFGF) and the addition of 1 μM all-trans retinoic acid. For the 
mesodermal differentiation protocol, undifferentiated monolayer hESC cultures 
were switched from E8 to differentiation medium with RPMI 1640 with B-27 
supplement without insulin (Life Technologies), which is a serum free growth 
supporting supplement and 12 µM CHIR99021 (Selleck Chemicals S2924, 
Houston, TX), a GSK-3 inhibitor that activates WNT signaling (Lian et al., 2013). 
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For the endodermal differentiation protocol, undifferentiated monolayer hESC 
cultures were switched from E8 to differentiation medium with RPMI 1640 with 
1X Glutamax and 100 ng/mL Activin A (R&D Systems, Minneapolis, MN). For 
treatment past 24h, 0.2% FBS was added (D’Amour et al., 2005). 
 
2.2.2 Microarray Expression Analysis 
RNA was extracted using Trizol Reagent (Life Technologies) according to the 
manufacturer’s protocol. Genomic DNA was removed from isolated RNA using 
the Zymo DNA-Free RNA Kit, and then RNA quality was assessed using the 
Agilent 2100 BioAnalyzer. Fifty nanograms of RNA was used to synthesize cDNA 
using the GeneChip® WT PLUS Reagent Kit. The cDNA was hybridized to the 
Affymetrix GeneChip Human Transcriptome Array 2.0 for 16.5h overnight at 
45ºC. Arrays were stained using the Affymetrix GeneChip® Fluidics Station 450 
and scanned with the Affymetrix GeneChip® Scanner 3000. All target preparation 
and microarray hybridization/ scanning was performed in the VGN Microarray 
Facility at UVM. The dataset generated has been deposited in the NCBI Gene 
Expression Omnibus database according to MIAME guidelines with accession 
number GSE74004. 
 Due to evident fold change compression, Affymetrix (Santa Clara, CA) used a 
GC content leveling and signal space transformation to reduce background 
levels. Transformed CEL files were then imported into Affymetrix Expression 
Console Build 1.3.1.187 where the data were normalized using the default 
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Robust Multi-Array Average algorithm. Further analysis was performed using the 
Gene Level Differential Expression Analysis function available in the Affymetrix 
Transcriptome Analysis Console Version 1.0.0.234. Differential gene expression 
was defined as a fold change greater than 1.5, an ANOVA p value less than 
0.05, and a FDR p value less than 0.05. Partek Genomic Suite software (St. 
Louis, MO) was used to generate the principal component analysis (PCA). 
EulerAPE version 3.0.0 was used to generate the proportional Venn Diagram 
and then recolored (Micallef and Rodgers, 2014). The heatmap was visualized 
using the heatmap.2 function in the R language package (http://www.r-
project.org/). Pathway analysis was performed using QIAGEN’s Ingenuity 
Pathways Analysis (Qiagen, Valencia, CA, www.qiagen/com/ingenuity) and 
Reactome – A Curated Pathway Database (http://www.reactome.org/) v53 (Croft 
et al., 2014; Milacic et al., 2012). 
 
2.2.3 Quantitative Real-Time PCR Analysis 
RNA was isolated as described for microarray analysis; however, cDNA was 
synthesized with random hexamer primers using Super Script III First Strand 
Synthesis System (Life Technologies Cat No. 18080-051). QRT-PCR was 
performed using SYBR Green PCR Master Mix (Bio-Rad, Hercules, CA) and 
samples were normalized to HPRT and fold change was determined using the 
ΔΔCt method. Primers used are as specified in Table 2.1. 
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Gene Primer Sequence SOX17 FW CGCACGGAATTTGAACAGTA 
REV GGATCAGGGACCTGTCACAC PAX6 FW CTTTGCTTGGGAAATCCGAG 
REV AGCCAGGTTGCGAAGAACTC 
MESP1 FW GAAGTGGTTCCTTGGCAGAC REV TCCTGCTTGCCTCAAAGTGT NESTIN FW GAAACAGCCATAGAGGGCAAA REV TGGTTTTCCAGAGTCTTCAGTGA GBX2 FW GTTCCACTGCAAAAAGTACCTCT REV GGGACGACGATCTTAGGGTTC BRACHYURY FW TGCTTCCCTGAGACCCAGTT REV GATCACTTCTTTCCTTTGCATCAAG MIXL1 FW GGTACCCCGACATCCACTTG REV TAATCTCCGGCCTAGCCAAA GATA4 FW TCCAAACCAGAAAACGGAAG  REV GAAGGCTCTCACTGCCTGAA AFP FW AAATGCGTTTCTCGTTGCTT  REV GCCACAGGCCAATAGTTTGT HPRT1 FW TGCTGACCTGCTGGATTACA  REV TCCCCTGTTGACTGGTCATT WEE1 FW ATTTCTCTGCGTGGGCAGAAG REV CAAAAGGAGATCCTTCAACTCTGC GSC FW GAGGAGAAAGTGGAGGTCTGGTT REV CTCTGATGAGGACCGCTTCTG FOXA2 FW GCATTCCCAATCTTGACACGGTGA REV GCCCTTGCAGCCAGAATACACATT DDIT4 FW TGAGGATGAACACTTGTGTGC REV CCAACTGGCTAGGCATCAGC GADD45B FW CGGTGGAGGAGCTTTTGGTG REV CACCCGCACGATGTTGATGT NFKB1A FW CTCCGAGACTTTCGAGGAAATAC REV GCCATTGTAGTTGGTAGCCTTCA OCT4 FW GAGAAGGAGAAGCTGGAGCA REV CTTCTGCTTCAGGAGCTTGG NANOG FW CAGAAGGCCTCAGCACCTAC 
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REV ATTGGAAGGTTCCCAGTCG SOX2 FW CATGTCCCAGCACTACCAG REV CTCCCATTTCCCTCGTTTTT Table 2.1 qRT-PCR Primers used in Chapter II. 
 
2.2.4 BrdU Incorporation Assay and Immunofluorescence (IF) Microscopy 
Cells were grown on Matrigel-coated coverslips for IF time points less than 24h 
and grown on Matrigel-coated 35mm MatTek glass bottom dishes (MatTek 
P35G-1.5-14-C, Ashland, MA) for BrdU incorporation and IF longer than 24h to 
allow for increased adhesion to the glass. For the BrdU incorporation assay, cells 
were incubated for 30 min at 37ºC with 10 µM 5-Bromo-2-deoxyuridine (Roche 
Kit No. 11 296 736 001, Basel, Switzerland) to allow for incorporation before 
fixation. Fixation was performed using 3.7% formaldehyde in phosphate buffered 
saline (PBS) for 10 min. Cells were then permeabilized in 0.1% Triton X-100 in 
PBS, and washed in 0.5% bovine serum albumin in PBS. For the BrdU 
incorporation assay, cells were treated with DNaseI (30 µg per million cells) (BD 
Biosciences, Franklin Lakes, NJ) for 1h at 37ºC after permeabilzation to expose 
the incorporated BrdU. Detection was performed using a rabbit polyclonal 
BRACHYURY antibody (H-210) (Santa Cruz Biotechnology Cat. No. sc-20109, 
Dallas, TX), a mouse monoclonal antibody (3B10) to SOX17 (Abcam ab84990, 
Cambridge, MA), a mouse monoclonal anti-BrdU antibody (clone MBG 6H8 igG1 
from Roche), a rabbit polyclonal Ki67 antibody (Santa Cruz Cat. No. sc-15402), 
or a rabbit polyclonal WEE1 antibody (Cell Signaling #4936, Danvers, MA). 
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Staining was performed using fluorescent secondary antibodies; for rabbit 
polyclonal antibodies a goat anti-rabbit IgG (H+L) secondary antibody, Alexa 
Fluor® 568 conjugate (Life Technologies A-11011), was used and for mouse 
monoclonal a F(ab')2-goat anti-mouse IgG (H+L) secondary antibody, Alexa 
Fluor® 647 conjugate was used (Life Technologies A-21237). 
 
2.2.5 Proliferation and Cell Viability 
For growth curves, cells were plated in 12 well plates. The next day, cells were 
counted and this value was taken as D0, and differentiation was initiated in half 
of the wells. Counting was performed at the same time daily for five additional 
days until confluence was reached. Cell Viability was assessed using the 
LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian cells (Life Technologies 
L3224) and was performed per manufacturer’s instructions, with viable cells 
staining green and dead cells staining red. 
 
2.2.6 Western Blot 
Whole cell lysates were generated by incubating cells in RIPA buffer for 30 min 
on ice, followed by sonication using a Covaris S-220 Ultrasonic Processor for 5 
min. Lysates were separated in a 12% polyacrylamide gel and transferred to 
PVDF membranes (Millipore, Billerica, MA) using an OWL semi-dry transfer 
apparatus. Membranes were blocked using 1% Blotting Grade Blocker Non-Fat 
Dry Milk (Bio-Rad) and incubated overnight at 4°C with the following primary 
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antibodies: a rabbit polyclonal WEE1 (Cell Signaling #4936, 1:1000); a rabbit 
polyclonal to CDK1(phospho Y15) (Abcam ab47594, 1:1000); a mouse 
monoclonal to CDK1/Cdc2 p34(17) (Santa Cruz sc-54, 1:1000); a rabbit 
polyclonal to CDK2 (M2) (Santa Cruz sc-163, 1:2000); a mouse monoclonal to 
GAPDH (0411) (Santa Cruz sc-47724). Secondary antibodies conjugated to HRP 
(Santa Cruz) were used for immunodetection, along with the Clarity Western ECL 
Substrate (Bio-Rad) on a Chemidoc XRS+ imaging system (Bio-Rad). Relative 
quantification was performed using the Image Lab Software (Bio-Rad) version 
5.1. 
 
2.2.7 WEE1 Inhibition 
Inhibition of WEE1 was accomplished using MK-1775 (Selleck Chemicals S1525, 
Munich, Germany) diluted from 10 mM/1 mL DMSO to 100 nM or Wee1 Inhibitor 
II (Millipore 681641), also at 100 nM. Cells were treated from initiation of 
differentiation to 8h, 16h, or 24h of differentiation. For differentiation longer than 
24h, the inhibitor was removed after 24h of treatment. 
 
2.2.8 Flow Cytometry Analysis 
Cells analyzed by flow cytometry were fixed for 10 min in 1% formaldehyde 
followed by 5 min of incubation with 0.125M glycine (Sigma-Aldrich, St. Louis, 
MO). Then cells were permeabilized for 10 min (BD Biosciences, 51-2091KZ) 
before being stained for 30 min with an antibody against H3S28P (Alexa fluor 
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647-conjugated, BD Biosciences, 558609). Cells were then re-suspended in 2% 
FBS in PBS and stained with 1 µg/ml DAPI (Life Technologies D1306) for at least 
30 min to determine DNA content. Flow cytometric analysis was performed using 
the LSRII instrument (BD Biosciences) with 640 nm laser for Alexa Fluor-647 
(670/30 BP) and 355 nm laser for DAPI (440/40 BP). Compensation for AF647-
DAPI was not applicable. DNA cell cycle profiles were analyzed using ModFit LT 
v4.1.7 software (Verity Software House, Topsham, ME). FlowJo (Ashland, OR) 
version 10 was used to display DNA histograms and to determine the percent of 
cells positive for H3S28P within the cycling cell populations. 
 
2.2.9 Statistical Analysis 
Statistically significant differences were determined using unpaired Student’s t 
tests with Welch’s correction unless otherwise indicated with GraphPad Prism 6 
software (GraphPad Software, La Jolla, CA). In order to determine the statistical 
significance associated with the measured percentage of a subset within the 
FACS data, the precision was calculated based on the Poisson statistical 
distribution. This confidence value takes into account the number of events 
measured and the number of events in the gated population. 
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2.3 Results 
2.3.1 Human Embryonic Stem Cells Differentiated into Mesendodermal 
Lineages Pause in the G2 Phase of the Cell Cycle 
 We investigated the relationship between cell cycle progression and early 
lineage commitment of hESCs by initially comparing the proliferation rates of 
pluripotent cells with those of hESCs that were differentiated into mesendoderm 
(Nishikawa et al., 1998; Tada, 2005). As previously shown (Becker et al., 2006), 
hESCs grown under pluripotent conditions exhibited exponential growth with a 
doubling time of <17h, while differentiating hESCs had a biphasic growth curve 
(Figure 2.1A). Notably, hESCs exhibited a longer doubling time of ~47h from 
days 1-3 of differentiation that by days 3-5 was reduced to ~27h, comparable to 
somatic diploid cells. These findings are consistent with previous studies that 
show a lengthening of the G1 phase after 72h of differentiation (Becker et al., 
2010).   
 To delineate mechanisms underlying the extended doubling time, we 
examined the cell cycle profile of hESCs during the first three days of 
mesendoderm differentiation. Cell populations stained with DAPI were assessed 
for DNA content by fluorescence activated cell analysis (Figure 2.1B and 2.2). 
Undifferentiated hESCs showed approximately 50% of cells in S phase, a typical 
cell cycle profile for hESCs. As early as 8h after induction of differentiation, cells 
began to accumulate in S/G2 phases, with a decrease in the G1 population 
(Figure 2.1B, 2.1C and 2.2). Accumulation in G2/M continued from 12-24 h, with 
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the greatest number of G2/M cells observed at 16h. By 72h of differentiation, 
cells were distributed throughout the cell cycle and by 96h, the percentage of 
cells in G2/M had decreased to nearly pre-pause levels (Figure 2.2). These 
findings indicate that cells pause in the late S, G2 or M phase of the cell cycle 
during the first cell cycle of mesendodermal differentiation. 
 To determine the specific phase of the cell cycle when differentiating hESCs 
pause, we first investigated whether pausing occurs in late S or G2 phases by 
measuring active DNA synthesis using BrdU incorporation and 
immunofluorescence (IF) microscopy (Figure 2.1D). Undifferentiated hESCs had 
approximately 70% BrdU positive cells, which was nearly unchanged at 8h. 
Consistent with the DNA content profiles obtained by flow cytometry (Figure 
2.1B), the percentage of BrdU positive cells was significantly decreased at 16h of 
differentiation, indicating fewer cells were synthesizing DNA. Furthermore, 
fluorescence microscopy of DAPI stained cells indicated an increase in nuclear 
size, a hallmark of G2 cells (Figure 2.1D). To confirm the hESCs were alive and 
actively proliferating, cells were evaluated using a viability stain and an antibody 
against Ki67, a marker of active proliferation (Figure 2.1D and 2.3). Greater than 
95% of cells were proliferating and viable, as determined by positive Ki67 
staining and by the presence of ubiquitous intracellular esterase activity detected 
by green fluorescence, respectively (Figure 2.1D and 2.3). These results exclude 
the possibility that the cell cycle pause is in S phase. FACS analysis using the 
mitotic marker H3S28P (Goto et al., 1999), along with DNA content staining, 
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revealed no increase in mitotic cells during the cell cycle pause (Figure 2.1E). 
Rather, mitotic cells decreased from 2.3% to 1.9% by 16h, concomitant with an 
increase in cells with 4N DNA content. Taken together these findings indicate 
that hESCs exhibit a G2 cell cycle pause during early differentiation towards 
mesendodermal lineages. 
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Figure 2.1. Human embryonic stem cells (hESCs) induced to differentiate into mesendoderm pause in G2. (A) Growth Curves for hESCs under pluripotent and differentiation conditions. Line graph represents mean±SD from three independent experiments each with a technical replicate (N= 6). (B) Representative flow cytometric analysis of DNA content by DAPI staining over a differentiation time course. Note the accumulation of cells in G2 between the 8h and 24h time points. (C) Percentages of cells in each phase (G1, S, G2, and Mitosis) at each time point during mesendoderm differentiation, as determined by cell cycle profile analysis using ModFit (G1, S, and G2 phases) and FlowJo (M phase, by determining the expression of H3S28P) software. Data represents mean±SD for three independent experiments (N=3). (D) Representative immunofluorescence images showing BrdU (yellow), and Ki67 (red) at time 
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points indicated. Nuclei are stained with DAPI (blue) (scale bars: 10 µm). Quantification of BrdU+ cells was performed using blind scoring in duplicate of 200 cells, data represents mean±SEM (*, p < 0.001). Significance was calculated by performing Student’s t tests with Welch’s correction between the undifferentiated state and the differentiated conditions. (E) Representative flow cytometric analysis during differentiation time course shown as H3S28P vs. DNA content with the percentage of mitotic cells indicated in the upper right corner.              
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Figure 2.3. Analysis of viability during mesendoderm differentiation. LIVE/DEAD staining showing that the majority of cells attached to the plate are viable and living (scale bars indicate 100 µm).  
2.3.2 Gene Expression Profiling of Early Mesendoderm Differentiation 
Identifies a Cluster of Differentially Expressed Genes Involved in the G2/M 
Transition  
 We examined global gene expression during early mesendoderm 
differentiation. Differentiation into mesendodermal lineages was confirmed by IF 
microscopy, and qRT-PCR for the mesoderm/primitive streak marker 
BRACHYURY and the endodermal marker SOX17, as well as the initiation of the 
decrease in pluripotency makers (Figure 2.4A, see Figure 2.5 for additional 
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lineage markers, and Figure 2.6 for pluripotency markers and an enlarged IF 
image of SOX17 staining at 72h). We performed microarray analysis at four time 
points (0h, 8h, 24h, 72h) with three independent biological replicates at each 
point. Reproducibility of the gene expression datasets is demonstrated by 
principal component analysis, which shows the undifferentiated hESC samples 
cluster away from the differentiated samples (Figure 2.4B). Bioinformatics 
analysis (see materials and methods for details) identified a large number of 
genes that were changed from 8h of differentiation onward (1080, ~27%), as well 
as from 24h onward (1016, ~25.5%), which indicates the progressive nature of 
the differentiation (Figure 2.4C).   
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Figure 2.4. Transcriptome analysis of early differentiation into mesendoderm. (A) Representative immunofluorescence staining of BRACHYURY (red) and SOX17 (green) over a mesendodermal differentiation time course. Green arrows point to cells staining positive for SOX17, as expression is very low. Nuclei are stained with DAPI (blue) (scale bars: 20 µm). (B) Principal Component Analysis (PCA) of the time points and replicates for mesendodermal differentiation of hESCs from global expression profiling of four time points (Undifferentiated (0h), 8 hours (8h), 1 day (24h), and 3 days (72h)) (n=3) by microarray analysis. (C) Venn diagram of the number of genes with expression changes greater than 1.5 fold, and p value and FDR p values < 0.05, at each time point compared to undifferentiated hESCs. The total number of genes changed at each time point is in brackets.  
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  Figure 2.5. qRT-PCR panel of mesendodermal differentiation. Early mesoderm markers (BRACHYURY, MIXL1, and MESP1), early ectoderm markers (PAX6, NES, and GBX2) and early endoderm markers (SOX17, GATA4, and AFP) were used. Data represents mean±SD for four independent experiment each with a technical replicate (N=8).  
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0.05 at any time point relative to undifferentiated levels (Figure 2.7). We focused 
on gene clusters 2 and 9 that had peak expression at 8h of mesendoderm 
differentiation, which corresponds to the initiation of the cell cycle pause (Table 
2.2). Cluster 9 contained only EGR1, an early response gene that is expressed 
but non-essential in early differentiation (Edwards et al., 1991; Lanoix et al., 
1991; Lee et al., 1995). Reactome pathway analysis revealed that Cluster 2 had 
an enrichment of genes involved in the G2/M DNA replication checkpoint and in 
cyclin A/B1 associated events during G2/M (Table 2.3). These findings point to 
G2/M regulatory pathways as critical determinants of the observed G2 cell cycle 
pause during mesendodermal differentiation. 
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Figure 2.7. Hierarchical clustering identifies a cluster of genes involved with the G2/M transition that increases at the time of the cell cycle pause. Hierarchical clustering based on normalized expression values of four time points was performed on annotated genes whose expression levels changed greater than 1.5 fold and p value and p value FDR < 0.05 at any time point compared to undifferentiated hESCs. Nine clusters were generated with the number of genes in each cluster indicated in brackets over the trace of the expression pattern. Clusters were analyzed using Reactome and Cluster 2 was found to have enrichment in pathways involved in the G2/M transition.   ABTB2 ARAP2 CASP3 CER1 CNN1 CREB5 
DDIT4 DNAJB5 EIF2AK3 ELL2 ETS2 FOSL2 
ID1 IFFO2 KLF6 MIR21 MMP13 MT1A 
MT1CP MT1E MT1F MT1X MT2A  NFKB1 
NOG NUAK2 PDGFB PLAU RHOB  SDC4 
STMN4 THBS1 TNFAIP3 USP53 WEE1 ZFP36 Table 2.2. Genes in Cluster 2. 
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regulated by multiple activating and inhibitory phosphorylations of CDK1/CDC2 
(Stark and Taylor, 2006; Vermeulen et al., 2003). WEE1, a kinase responsible for 
inhibitory phosphorylation of CDK1 at Y15 (McGowan and Russell, 1993), had 
the highest level of RNA expression during the cell cycle pause when compared 
to the other  Cluster 2 genes (Figure 2.8B, and 2.9). WEE1 was also up-
regulated on the protein level during the cell cycle pause (Figure 2.8C-D), and IF 
microscopy confirmed that the increased WEE1 protein was largely localized in 
the nucleus (Figure 2.8E), as expected (McGowan and Russell, 1995). 
Importantly, there was a corresponding increase in the inhibitory phosphorylation 
of CDK1 on Y15 during the cell cycle pause (Figure 2.8C, D). Together, these 
observations indicate that the increased WEE1 is functional and inhibiting 
progress into mitosis, and suggest a link between the cell cycle pause during 
early mesendoderm differentiation of hESCs and WEE1 activity. 
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Figure 2.8. WEE1, a G2/M regulator, is up-regulated during the G2 cell cycle pause. (A) Using Ingenuity to analyze Cluster 2, genes were selected that 
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related to cell cycle progression/ regulation, and G2/M associated genes were mapped. (B) Expression profiles of the four known regulators of G2 phase progression. The graph shows microarray expression levels as log2 values. Data represents mean±SD from three independent experiments (N=3). (C) Representative Western blot showing the levels of WEE1, pCDK1 Y15, and CDK1 in hESCs induced to differentiate to mesendoderm. GAPDH is used as a loading control. The two arrows indicate the separation between the phosphorylated and unphosphorylated states of CDK1. (D) Quantification of Western blots represented in (C). Quantification data is the mean±SD from two independent experiments with a technical replicate of each (N=4). The dotted line is set at one, which is the initial normalized value for the undifferentiated stae. (E) Representative immunofluorescence images with WEE1 (red). Nuclei are stained with DAPI (blue) (scale bars: 100 µm).  
 
Figure 2.9. qRT-panel of G2 regulators. Confirmation of overall microarray expression levels for WEE1, DDIT4, GADD45B, and NFKBIA by qRT-PCR. Data is the mean±SD from three independent experiments with a technical replicate of each (N=6).  2.3.4 Induction of WEE1 Expression and the G2 Cell Cycle Pause Are 
Lineage-Specific 
 We investigated whether the G2 cell cycle pause is a general feature of early 
differentiation, or is lineage specific. Human ESCs were differentiated into 
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ectoderm, mesoderm, or endoderm and evaluated at 0h (undifferentiated), 8h, 
16h, and 24h after induction of differentiation. Commitment to the desired 
lineages was confirmed by qRT-PCR on a panel of lineage-restrictive 
transcription factors RNAs (Figure 2.10, and see Figure 2.11 for phase contrast 
images of differentiation). The cell cycle distribution for each differentiation time 
course was quantified using flow cytometric analyses of H3S28P mitotic staining, 
along with DNA content (Figure 2.12A-F and 2.13). Similar to mesendodermal 
differentiation, we observed an accumulation of cells in G2 during endodermal 
differentiation, which became prominent at 16h and continued through 24h 
(Figure 2.12A, D). Although an enrichment of cells in G2 was seen at 16h of 
mesodermal differentiation, it did not extend to 24h, and involved a smaller 
percentage of the cells (Figure 2.12B, E). Of note, there was an increase in the 
percent of cells in S phase at 8h during both endodermal and mesodermal 
differentiation (Figure 2.12D, E). Consistent with the G2 cell cycle pause, WEE1 
RNA levels were increased at 8h in both mesodermal and endodermal 
differentiation (Figure 2.12G). No cell cycle stage specific accumulation or WEE1 
up-regulation was detected during ectodermal differentiation (Figure 2.12C, F, 
G). These findings establish that the G2 pause is lineage restricted and also 
reveal a correlation between WEE1 up-regulation and the G2 cell cycle pause. 
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Figure 2.10. qRT-panel of differentiation directed to ectoderm, mesoderm, and endoderm. Early markers for mesoderm (BRACHYURY, MIXL1, and MESP1), ectoderm (PAX6, NES, GBX2) and endoderm (SOX17, GATA4, AFP) were examined. Data is the mean±SD from three independent experiments with a technical replicate of each (N=6).  
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  Figure 2.11. Phase Contrast images across mesoderm, ectoderm, and endoderm differentiation time courses. All images were taken at 10x magnification.  
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Figure 2.12. Differentiation to endoderm and mesoderm induces a cell cycle pause and expression of WEE1. (A-C) Representative flow cytometric DNA content analysis by DAPI staining across differentiation time courses to (A) Endoderm (B) Mesoderm and (C) Ectoderm. (D-F) Quantification of flow cytometric DNA content analysis by DAPI staining for differentiation to (D) Endoderm (E) Mesoderm and (F) Ectoderm, showing enrichment in the G2 population in both mesoderm and endoderm differentiation. The percentage of cells in each phase (G1, S, G2, and Mitosis) at each time point during differentiation was determined by cell cycle profile analysis using Flow Jo and ModFit. Data represents the mean of three independent experiments normalized to 100%. (G) The levels of WEE1 normalized to HPRT, during endoderm, mesoderm, and ectoderm differentiation by qRT-PCR. A significant increase in 
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WEE1 expression is seen during mesoderm and endoderm differentiation. Data represented as mean±SD from three independent experiments, with a technical replicate each (N=6) (*, p < 0.05).  
  Figure 2.13. ModFit profiles across mesoderm, ectoderm, and endoderm differentiation time courses with the percentage of cells in each cell cycle phase.       
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2.3.5 Inhibition of WEE1-Mediated CDK1 Phosphorylation Compromises 
Endodermal Differentiation 
 To experimentally test whether WEE1 plays a functional role in the G2 cell 
cycle pause, we blocked the ability of WEE1 to phosphorylate Y15 of CDK1 
using the WEE1 selective inhibitor MK-1775 (Guertin et al., 2013; Krajewska et 
al., 2013; Kreahling et al., 2012) or Wee1 Inhibitor II (Palmer et al., 2006). 
Inhibition of WEE1 activity by MK-1775 in cells differentiating into mesendoderm 
significantly increased the percentage of mitotic cells at 16h (3.69±0.15% with 
MK-1775 vs. 2.33±0.11% in uninhibited cells) and 24h (3.29±0.14% with MK-
1775 vs. without treatment 2.31±0.11%) (Figure 2.14A). Similar results were 
seen with treatment with Wee1 Inhibitor II, though a larger, significant increase in 
mitotic cells was observed at 8h (Figure 2.15A). Importantly, in the presence of 
MK-1775, there was no observable enrichment of cells in G2, indicating that the 
cell cycle pause was prevented (Figure 2.14A and 2.16). Western blot analysis 
confirmed that inhibition of WEE1 activity decreased CDK1 Y15 phosphorylation 
(Figure 2.14B). These results demonstrate that WEE1-mediated inhibitory 
phosphorylation of CDK1 is a key regulatory event in the G2 cell cycle pause.  
  We investigated whether the WEE1-mediated cell cycle pause was 
necessary for lineage commitment to either mesodermal or endodermal lineages. 
Differentiating cells were treated with the WEE1 inhibitor and expression of 
lineage restrictive transcription factors was measured by qRT-PCR. During 
endodermal differentiation, inhibition of WEE1 activity significantly decreased the 
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levels of the key lineage determinants SOX17 and FOXA2 (D’Amour et al., 2005; 
Sulzbacher et al., 2009) by 72h (Figure 2.14C). In contrast, MK-1775 did not 
significantly affect expression of lineage markers during mesodermal 
differentiation (Figure 2.14D). These findings indicate that the cell cycle pause 
mediated by the WEE1-CDK1 pathway is necessary for endodermal, but not 
mesodermal differentiation. 
 Wee1 Inhibitor II had less efficacy in inhibiting WEE1, evidenced by the 
substantial number of cells still paused in the G2 phase at 16h and 24h (Figure 
2.15A and 2.16) and the smaller decrease in CDK1 Y15 phosphorylation with 
treatment with inhibitor when compared with MK-1775 treatment (Figure 2.15B). 
However, even with this decreased efficacy, treatment with Wee1 Inhibitor II 
exhibited similar results to treatment with MK-1775. During directed 
differentiation treatment with Wee1 Inhibitor II decreased the levels of 
endodermal markers (though not statistically significant) and had no significant 
effect on mesodermal differentiation lineage marker expression (Figure 2.15C 
and 2.15D). These results obtained using the second WEE1 inhibitor reinforce 
the conclusion that the cell cycle pause mediated by the WEE1-CDK1 pathway is 
necessary for endodermal, but not mesodermal differentiation. 
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Figure 2.14. WEE1 inhibition compromises endodermal differentiation. (A) Representative flow cytometric analysis of hESCs undergoing mesendodermal differentiation treated with WEE1 inhibitor, MK-1775, shown as H3S28P vs. DNA content with the percentage of mitotic cells indicated in the upper right corner. This panel shows an increase in mitotic population with treatment with the WEE1 inhibitor at 16h and 24h. (B) Representative Western blot showing the levels of pCDK1 Y15, and CDK1 in hESCs induced to differentiate to mesendoderm with and without treatment with MK-1775. CDK2 is used as a loading control. The two arrows indicate the separation between the phosphorylated and unphosphorylated states of CDK1. The numbers above each band of the Western blot indicate the relative quantification of that band normalized to the loading control. (C) After 48h and 72h of differentiation directed to endoderm, with and without 24h treatment with MK-1775, the levels of endoderm markers SOX17 and FOXA2 were measured by qRT-PCR. Data represented as 
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mean±SD from three independent experiments, with a technical replicate each (N=6) (D) A time course of differentiation directed to mesoderm, with and without treatment with the WEE1 inhibitor MK-1775, the levels of mesoderm markers BRACHYURY, MIXL1, GSC, and MESP1 were measured by qRT-PCR. qRT-PCR data shown as mean±SD from three independent experiments with a technical replicate each (N=6) (***, p < 0.001; *, p<0.05). 
 Figure 2.15. A second WEE1 inhibitor with lower efficacy show similar effects to use of MK-1775. (A) Representative flow cytometric analysis of hESCs undergoing mesendodermal differentiation either untreated or treated with WEE1 inhibitor II, shown as H3S28P vs. DNA content with the percentage of mitotic cells indicated in the upper right corner. This panel shows an increase in mitotic population with treatment with the WEE1 inhibitor at 8h and 16h. (B) Representative Western blot showing the levels of pCDK1 Y15, and CDK1 in 
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hESCs induced to differentiate to mesendoderm with and without treatment with Wee1 Inhibitor II. GAPDH is used as a loading control. The numbers above each band of the Western blot indicate the relative quantification of that band normalized to the loading control. (C) After 48h and 72h of differentiation directed to endoderm, with and without 24h treatment with MK-1775 or Wee1 Inhibitor II, the levels of endoderm markers SOX17 and FOXA2 were measured by qRT-PCR. Data represented as mean±SD from three independent experiments, with a technical replicate each (N=6) (D) A time course of differentiation directed to mesoderm, with and without treatment with the MK-1775 or WEE1 inhibitor II, the levels of mesoderm markers BRACHYURY, MIXL1, GSC, and MESP1 were measured by qRT-PCR. qRT-PCR data shown as mean±SD from three independent experiments with a technical replicate each (N=6) (***, p < 0.001; *, p<0.05).  
 Figure 2.16. ModFit profiles across mesendoderm differentiation time courses with and without treatment of MK-1775 or the Wee1 Inhibitor II with the percentage of cells in each cell cycle phase.   
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2.4 Discussion for Chapter II 
 In this chapter we have discovered mechanistic underpinnings linking the cell 
cycle and early events during human embryonic stem cell differentiation. Our 
findings identify a novel G2 cell cycle pause in early differentiation of human 
embryonic stem cells. This G2 pause is mediated by Y15 CDK1 phosphorylation 
due to an increase in the WEE1 kinase. Up-regulation of WEE1 and the cell cycle 
pause are observed during differentiation to both endodermal and mesodermal 
lineages, but only endoderm specification is compromised upon WEE inhibition 
(Figure 2.17). By 72 hours of differentiation the levels of WEE1 begin to 
decrease, as does the amount of inactivating phosphorylation on CDK1 Y15 
(Figure 2.8C-E), and the number of cells paused in G2 (Figure 2.1). This allows 
the balance between the opposing forces of the inactivating phosphorylation of 
WEE1 and the activing de-phosphorylation by CDC25 to return to normal, and 
allows cells to begin to progress more regularly through the cell cycle. We 
conclude that there is a WEE1-mediated cell cycle pause in G2 that when 
disrupted, selectively compromises lineage commitment to endoderm. 
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Figure 2.17. A summary model showing our finding of a novel G2 cell cycle pause.    Recent studies have focused on the role of the G1 phase in promoting 
differentiation of hESC (Pauklin and Vallier, 2013; Sela et al., 2012). Gonzalez et 
al examined pluripotent state dissolution and retinoic acid induced differentiation 
and found that the S and G2 phases of the cell cycle have intrinsic functions in 
pluripotent state maintenance (Gonzales et al., 2015). Our results have 
uncovered a previously unknown role for G2 events in regulating cell fate 
determination during the first cell cycle after induction of differentiation, and 
reveal that multiple mechanisms link cell cycle control to differentiation. The very 
early G2 pause we observed may function as a transition point between active 
maintenance of pluripotency and the incorporation of differentiation cues before 
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commitment to lineage determination. This could be beneficial to the cells to 
prevent premature or unintended differentiation. At a cellular mechanistic level, 
this G2 cell cycle pause could also be required to establish competency for 
chromatin rearrangement or movement of nuclear factors necessary for 
mediating differentiation. This could be tested by looking at the accessibility of 
chromatin, histone modifications, and binding of factors around the promoters of 
SOX17 and FOXA2 after directed differentiation to each of three germ layers in 
the presence and absence of a WEE1 inhibitor to see if there is a requirement for 
the G2 pause to obtain a certain permissive chromatin state.  
 Fifteen of the 42 genes that were up-regulated during the early stages of the 
cell cycle pause are involved in regulation of G2 or cell cycle progression. WEE1, 
the most highly up-regulated of these genes, and its phosphorylation of CDK1 
Y15 provide compelling functional linkage between the cell cycle and 
competency for lineage commitment. Our findings that additional genes are up-
regulated at the cell cycle pause suggest that other mechanisms may be 
operative at the G2/M transition during early differentiation. It remains to be 
determined whether these genes are upstream of WEE1 or function coordinately 
with WEE1.  
 The conclusions reached in this chapter regarding WEE1 inhibition preventing 
the G2 cell cycle pause that compromised endodermal differentiation could be 
strengthened by use of another WEE1 inhibitor that efficiently prevented the 
phosphorylation of CDK1 at Y15. Unfortunately, beyond MK-1775, there are not 
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well published selective inhibitors of WEE1 that are commercially available. An 
alternate strategy to further strengthen the evidence for the role of WEE1 in the 
G2 cell pause would be to knock down the WEE1 protein. One concern with 
knocking down the WEE1 protein would be that it would be more disruptive than 
only inhibiting the specific Y15 phosphorylation of CDK1. WEE1 may have 
additional roles in the cell, as the defects in WEE1 deficient cells were more 
serious than in cells with other defects in the G2/M checkpoint (Tominaga et al., 
2006). A second concern would be that in order to have WEE1 levels reduced 
before the 8h point of differentiation, WEE1 would have to be knocked down in 
pluripotent hESCs; however, when pluripotent hESCs were treated with MK-1775 
an extremely high level of cell death was observed. Additionally, RNAi 
approaches carry inherent limitations that include transfection efficiency 
(especially in hESCs) and off target effects. Similarly, mutating the Y15 residue 
of CDK1 to prevent phosphorylation with gene editing technology would have to 
be done in undifferentiated cells, prior to differentiation and by the time 
differentiation could be initiated, effects would be already accumulating. 
 From a physiological standpoint, the up-regulation of WEE1 and the G2 cell 
cycle pause are lineage restricted. Although WEE1 up-regulation occurs during 
commitment to both endodermal and mesodermal lineages, only differentiation to 
endoderm was compromised when WEE1 activity was inhibited. Neither the G2 
pause nor increased WEE1 was observed in ectodermal differentiation. This 
lineage restricted cell cycle pause could reflect a decision point for cell fate 
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determination of a bipotent progenitor with the ability to differentiate to either 
mesoderm or endoderm. Mesodermal differentiation may be the default pathway, 
because WEE1 inhibition compromises endodermal but not mesodermal 
differentiation.  
 In a broader biological context, our results may provide mechanistic insight 
into early events for lineage commitment that are mediated by crosstalk between 
regulatory components of the cell cycle and competency for initiation of 
phenotype. This crosstalk may be governed by selective expression of genes 
that control the cell cycle and those that sustain pluripotency or are permissive 
for the transition to developmental progression. We postulate that a G2 cell cycle 
pause in pluripotent cells provides a window of opportunity to reconfigure 
genomic and epigenetic regulatory machinery. These regulatory events permit a 
transition from unrestrained proliferation and suppression of lineage specific 
genes to restricted proliferation with physiologically responsive cell and tissue 
specific gene expression. 
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CHAPTER III. Transient RUNX1 Expression during Early Mesendodermal Differentiation of hESCs Promotes Epithelial to Mesenchymal Transition through TGFβ2 Signaling 
3.1 Introduction 
In this chapter, we investigated whether phenotype associated 
transcription factors may play an initial role in differentiation prior to their 
established function in specifying lineage identity. A candidate screen of 
phenotypic transcription factors identified RUNX1 as selectively and transiently 
upregulated as early as 8h during mesendodermal differentiation of hESCs. We 
investigated what role the early expressed phenotypic transcription factor RUNX1 
might play during differentiation in addition to its known role in association with 
hematopoietic lineage identity. 
 
 A large portion of this chapter has been submitted for publication as: 
VanOudenhove JJ, Medina, R, Ghule PN, Lian JB, Stein JL, Zaidi SK, Stein, GS. Transient RUNX1 Expression during Early Mesendodermal Differentiation of hESCs Promotes Epithelial to Mesenchymal Transition through TGFβ2 Signaling. Submitted to Stem Cell Reports.   
 All experiments were performed by Jennifer VanOudenhove, with the 
exception of the initially phenotypic transcription factor screen, which was 
performed by Ricardo Medina. All figures were created by Jennifer 
VanOudenhove, with the exception of 3.1A, which was created by Dr. Zaidi. 
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3.2 Materials and Methods 
3.2.1 Stem Cell Culture 
The female H9 (WA09) line and the male H1 (WA01) of hESCs were maintained 
on Matrigel and differentiated as previously reported (VanOudenhove et al., 
2016).  In short, mesendoderm differentiation was induced with Knockout DMEM, 
containing 20% heat inactivated Defined Fetal Bovine Serum (FBS), 1mM L-
glutamine with 1% v/v 2-mercaptoethanol, and 0.1 mM nonessential amino acids. 
Retinoic acid (RA)-induced ectodermal differentiation was induced by the 
addition of 1 μM all-trans retinoic acid (Sigma-Aldrich, St. Louis, MO). The 
mesodermal differentiation protocol induces differentiation by introducing medium 
containing RPMI 1640 with B-27 supplement without insulin (Life Technologies), 
which is a serum free growth supporting supplement and 12 µM CHIR99021 
(Selleck Chemicals S2924, Houston, TX), a GSK-3 inhibitor that activates WNT 
signaling. To produce endoderm, undifferentiated hESC cultures were switched 
to RPMI 1640 containing 1X Glutamax and 100 ng/mL Activin A (R&D Systems, 
Minneapolis, MN). For treatments past 24h, 0.2% FBS was added.  
 
3.2.2 Lentiviral RNAi 
H9 hESCs plated on Matrigel were transduced in 6-well plates with lentivirus 
carrying shRNA designed to knockdown RUNX1 (clone V2LHS_150257) or be 
non-silencing (Cat No. RHS4346) using the GIPZ Lentiviral RNAi System (GE, 
Lafayette, CO) in the presence of polybrene. After introduction of lentivirus, cells 
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were spun at 2000 rpm at 37⁰C for 45 minutes. Selection with 1 μg/ml puromycin 
(Sigma-Aldrich P7255-100MG) was performed for the first three passages after 
infection. 
 
3.2.3 Microarray Expression Analysis 
RNA was extracted using Trizol and prepared for microarray analysis as 
described previously (VanOudenhove et al., 2016). All target preparation and 
microarray hybridization/ scanning was performed in the VGN Microarray Facility 
at UVM. The datasets generated have been deposited in the NCBI Gene 
Expression Omnibus database according to MIAME guidelines with accession 
numbers GSE74004 and GSE79598. 
 Due to evident fold change compression, Affymetrix (Santa Clara, CA) used a 
GC content leveling and signal space transformation to reduce background 
levels. Analysis of data was performed using Affymetrix Expression Console 
Build 1.3.1.187 and the Affymetrix Transcriptome Analysis Console Version 
1.0.0.234. Differential gene expression was defined as a fold change greater 
than 1.5, an ANOVA p value less than 0.05, and a False Discovery Rate p value 
less than 0.05. Partek Genomic Suite software (St. Louis, MO) was used to 
generate the principal component analysis (PCA). EulerAPE version 3.0.0 was 
used to generate the proportional Venn Diagram and then recolored (Micallef and 
Rodgers, 2014). Pathway analysis was performed using QIAGEN’s Ingenuity 
Pathways Analysis (Qiagen, Valencia, CA, www.qiagen/com/ingenuity). GO term 
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analysis was performed using DAVID (Version 6.7) (Huang et al., 2009a, 2009b). 
The ClueGO plug-in for Cytoscape 2.8 (Version 1.8) was used for functional 
grouping GO analysis (Bindea et al., 2009). 
 
3.2.4 Quantitative Real-Time PCR Analysis 
RNA was isolated as described for microarray analysis, and cDNA was 
synthesized with random hexamer primers using Super Script III First Strand 
Synthesis System (Life Technologies Cat No. 18080-051). QRT-PCR was 
performed using SYBR Green PCR Master Mix (Bio-Rad, Hercules, CA) and 
samples were normalized to HPRT and fold change was determined using the 
ΔΔCt method. Primers used are as specified in Table 3.1. 
Gene for qPCR Primer Sequence PanRUNX1 FW AGCATGGTGGAGGTGCTG REV GATGGGCAGGGTCTTGTTG PanRUNX2 FW ACTTCCTGTGCTCGGTGCT REV CCGGAGCTCAGCAGAATAAT PanRUNX3 FW GAGGCTCACTCAGCACCAC REV TCGGAGAATGGGTTCAGTTC OCT4 FW GAGAAGGAGAAGCTGGAGCA REV CTTCTGCTTCAGGAGCTTGG NANOG FW CAGAAGGCCTCAGCACCTAC REV ATTGGAAGGTTCCCAGTCG Brachyury (T) FW TGCTTCCCTGAGACCCAGTT REV GATCACTTCTTTCCTTTGCATCAAG SOX17 FW AGCAGAATCCAGACCTGCAC REV CTTGTAGTTGGGGTGGTCCT PAX6 FW AGACACAGCCCTCACAAACA REV GCAGCATGCAGGAGTATGAG AFP FW AAATGCGTTTCTCGTTGCTT REV GCCACAGGCCAATAGTTTGT MIXL1 FW TCCAGGATCCAGGTATGGTT REV AGCCAAAGGTTGGAAGGATT 
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MYOD FW CCAGGATATGGAGCTACTGTC REV AACACGGGTCGTCATAGAAG PPARγ FW CCTATTGACCCAGAAAGCGATT  REV CATTACGGAGAGATCCACGGA  HPRT1 FW GACCAGTCAACAGGGGACAT REV CCTGACCAAGGAAAGCAAAG RUNX1a FW CACATGGGACAATTGTGAGG REV GTACCGGGATCCATGCTAAA RUNX1b FW GGCATGACAACCCTCTCTGC REV GCGTCGGGGAGTAGGTGAA RUNX1c FW GTTTCGCAGCGTGGTAAAAG REV AAGCACTGTGGGTACGAAGG TGFβ1 FW CGCGTGCTAATGGTGGAAAC REV GTTCAGGTACCGCTTCTCGG TGFβ2 FW CTTTGGATGCGGCCTATTGC REV TCCAGCACAGAAGTTGGCAT TGFβ3 FW GGGTCCATGAACCTAAGGGC REV AGGCAGATGCTTCAGGGTTC E-Cadherin (CDH1) FW GGAAGTCAGTTCAGACTCCAGCC REV AGGCCTTTTGACTGTAATCACACC Occludin FW GCAAAGTGAATGACAAGCGGT REV CTGTAACGAGGCTGCCTGAA CLD7 FW CCGAGGAGAGAGCACTTTGG REV TGGATTTCCCTCGAACACCG VIM FW AGGAAATGGCTCGTCACCTTCGTGAATA REV GGAGTGTCGGTTGTTAAGAACTAGAGCT TWIST1 FW TGAGCAAGATTCAGACCCTCA REV ATCCTCCAGACCGAGAAGG ZEB2 FW AAGCCAGGGACAGATCAGC REV CCACACTCTGTGCATTTGAACT SNAI 1 FW CCAATCGGAAGCCTAACTACAG REV GACAGAGTCCCAGATGAGCATT SNAI2 FW ACAGCGAACTGGACACACATAC REV GTATCCGGAAAGAGGAGAGAGG CD44 FW CCATTTTGCCCTTCCATAGC REV CAACCCCCAACCTCAGTGG Table 3.1. qRT-PCR Primers used in Chapter III. 
 
 
 
66  
3.2.5 Immunofluorescence (IF) Microscopy and RNA FISH 
Cells were grown on Matrigel-coated coverslips for IF and RNA FISH. Detection 
of RUNX1 protein was performed using a rabbit polyclonal RUNX1 antibody (Cell 
Signaling #4336, Danvers, MA). Staining was performed using a fluorescent 
secondary antibody to rabbit polyclonal antibodies; a goat anti-rabbit IgG (H+L) 
secondary antibody, Alexa Fluor® 488 conjugate (ThermoFisher Scientific Cat 
No. A-11001) (Waltham, MA). For RNA FISH, a RUNX1 probe was created using 
a BAC clone (RP11-299D9) spanning the RUNX1 gene locus, obtained from the 
BAC/PAC Resources at the Children’s Hospital Oakland Research Institute from 
the RPCI-11 Human Male BAC Library (Osoegawa et al., 2001, 1998) (See 
Figure 3.0). The BAC clone was amplified and isolated using the QIAGEN® 
Large-Construct Kit, and labeled by nick translation using the DIG-Nick 
Translation Mix (Roche Cat No. 11745816910, Basel, Switzerland). Hybridization 
and detection were carried out as previously reported (Byron et al., 2013), with 
the addition of a pepsin digest (5 mg/ml pepsin in a 1:2000 dilution in 0.01N HCl) 
to allow full penetrance of probe. Hybridization occurred overnight at 37⁰C. A 
Rhodamine anti-digoxygenin secondary antibody (Roche 11207750910) was 
used for signal detection. Images were taken on a Zeiss AxioImager microscope 
equipped with a Hamamatsu CCD camera and Metamorph imaging software. 
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3.2.7 Western Blot 
Whole cell lysates were generated by incubating cells in RIPA buffer for 30 min 
on ice, followed by sonication using a Covaris S-220 Ultrasonic Processor for 5 
min. Lysates were separated in an 8% polyacrylamide gel and transferred to 
PVDF membranes (Millipore, Billerica, MA) using an OWL semi-dry transfer 
apparatus. Membranes were blocked using 1% Blotting Grade Blocker Non-Fat 
Dry Milk (Bio-Rad) and incubated overnight at 4°C with the following primary 
antibodies: a rabbit polyclonal RUNX1 (Cell Signaling #4334, 1:1000); a goat 
polyclonal to OCT3/4 (Santa Cruz sc-8628, 1:1000); a rabbit polyclonal to CDK2 
(M2) (Santa Cruz sc-163, 1:2000); a mouse monoclonal to GAPDH (0411) 
(Santa Cruz sc-47724); a rabbit monoclonal to Smad2 (D43B4) (Cell Signaling 
#5339); a rabbit monoclonal to pSmad2 (Ser465/467) (138D4) (Cell Signaling 
#3108). Secondary antibodies conjugated to HRP (Santa Cruz) were used for 
immunodetection, along with the Clarity Western ECL Substrate (Bio-Rad) on a 
Chemidoc XRS+ imaging system (Bio-Rad). 
 
3.2.8 TGFβ Rescues 
Reintroduction of TGFβ1 (R&D Systems, 240-B) and TGFβ2 (R&D Systems, 
302-B2) reconstituted in 4 mM HCl was performed at 5.0 ng/ml. 
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3.2.9 Scratch Assays 
hESCs were plated and, 24h later, were induced to differentiate. Thirty hours into 
differentiation, Mitomycin C at 10 µg/ml was introduced to inhibit cell proliferation. 
After 48h of differentiation colonies were scratched down the center using a 
sterile 10µl pipette tip. Scratches were imaged by phase-contrast microscopy 
directly in the center of the colony, after being washed twice with medium, and 
marked. The scratch was imaged 18h later in the marked location. The scratch 
area was calculated using the Scratch Assay Analyzer plugin from MiToBo 
toolbox for ImageJ (Glaß et al., 2012). 
 
 
3.2.10 Chromatin Immunoprecipitation 
Cells after two days of mesendodermal differentiation, were cross-linked with 
0.8% formaldehyde (Sigma-Aldrich) in PBS for 10 min. The cells were washed 
twice, and lysed in a buffer containing 0.1% sodium deoxycholate, 0.5% N-
Lauroylsarcosine,1 mM EDTA, 1mM EGTA, 10 mM Tris-HCl (pH 8), and 1× 
protease inhibitor mixture. Lysates were sonicated to fragment chromatin DNA 
into ∼200-800 bp pieces using a Covaris S220 Sonicator (Covaris, Woburn, MA). 
Lysates were switched into a buffer containing 0.1% SDS,1 mM EDTA, 50 mM 
HEPES (pH 7.9), 140 mM NaCl, 1% Triton X-100, and 1× protease inhibitor 
mixture. Sheared chromatin was used for immunoprecipitation with RUNX1 
antibody (Cell Signaling #4334) or immunoglobulin G (IgG) (12-370, Millipore) 
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overnight at 4 °C. Subsequently, the immunoprecipitation mixture was incubated 
with Protein-G Dynabeads (ThermoFisher #10003D) for an additional 3h at 4 °C. 
Precipitated chromatin was washed with salt solutions of increasing 
concentration, and eluted into a buffer containing 1% SDS, and 0.1 M NaHCO3. 
The cross-linking was reversed and DNA was recovered using the QiaQuick 
PCR purification kit (Qiagen #28104). Primers targeting the promoters of the 
listed genes that were used for qPCR are in Table 3.2. 
Genes for ChIP Primer Sequence TGFβ1 FW TCTGGGGTTGCCTTCATCTA REV CAGCATTTGGGAAAGGAGAG TGFβ2 FW AACATAGTGGATCCTGACTGCAA REV TCTGGCAGATGAGGAGACTGA RUNX1 FW CTCCCGGGGCCTCTCATC REV CGCCGGGGAGCTTAATTG Table 3.2. ChIP qPCR Primers. 
3.2.11 Statistical Analysis 
Statistically significant differences were determined using unpaired Student’s t 
tests with Welch’s correction with GraphPad Prism 6 software (GraphPad 
Software, La Jolla, CA). 
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3.3 Results 
3.3.1 RUNX1 is Transiently and Selectively Upregulated During Early 
Mesendodermal Differentiation of Human Embryonic Stem Cells  
 To investigate whether phenotype associated transcription factors play a role 
in early hESC differentiation prior to their established role in control of lineage 
identity, we screened expression of candidate transcription factors using qRT-
PCR analysis. We induced mesendodermal differentiation as described in the 
experimental procedures, and ensured mesendodermal commitment of hESCs 
by evaluating the expression of known markers of mesendoderm (Mahmood and 
Aldahmash, 2015; Tada, 2005; VanOudenhove et al., 2016). As expected 
BRACHYURY, MIXL1, and MESP1 were upregulated (Figure 3.1A). In our 
screen of candidate transcription factors we looked at over twenty candidates 
that included among others: TDGF1, GATA4, AFP, PDGFRA, CDX2, PAX6, 
FGF5, SOX17, GATA6, GATA2, RUNX1, RUNX2, RUNX3, PPARγ, MYH6, 
MYOD, OCT4, NANOG, SOX2 (a selection are included in Figure 3.1B). We 
discovered RUNX1 was the only candidate factor selectively and transiently 
upregulated as early as 4-8hrs following induction of differentiation (Figure 3.1B).  
 Different RUNX1 isoforms (Figure 3.1C) are linked to distinct biological 
processes (Brady et al., 2013; Challen and Goodell, 2010; Ran et al., 2013). 
Importantly, the RUNX1c isoform, transcribed from the P1 promoter, is 
expressed at the time of emergence of definitive hematopoietic precursors, while 
RUNX1b, transcribed from the P2 promoter, is more widely expressed 
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(Sroczynska et al., 2009). Therefore, we used specific primers to examine 
relative levels of each RUNX1 isoform. We discovered that the RUNX1b isoform 
was the predominantly expressed transcript in two different hESC lines, the 
female (H9) and male (H1), during mesendodermal differentiation (Figure 3.1C).  
 We next examined the levels of total RUNX1 transcripts during endodermal 
(D’Amour et al., 2005), mesodermal (Lian et al., 2013), and ectodermal (Tonge 
and Andrews, 2010) differentiation of hESCs to determine whether expression is 
lineage specific (Figure 3.1D). RUNX1 was expressed during both endodermal 
and mesodermal, but not ectodermal differentiation, confirming the 
mesendodermal specificity. Furthermore, RNA FISH (fluorescence in situ 
hybridization) revealed that >98% of colonies and >95% of cells exhibited 
RUNX1 expression during mesendodermal differentiation (Figure 3.1E). The 
majority of cells had two nuclear foci, consistent with two sites of transcription. In 
agreement with the RNA expression data, there was a complete lack of RUNX1 
foci in undifferentiated hESCs (Figure 3.1E). These findings establish that 
RUNX1 transcripts are transiently and selectively expressed in mesendodermal 
lineage commitment. 
 Because several post transcriptional mechanisms can prevent translation (R. 
J. Jackson et al., 2010), we investigated whether the RUNX1 RNA was 
translated into protein. Both H1 and H9 hESC lines were subjected to early 
mesendodermal differentiation. Western blot analysis showed that RUNX1 
protein was detectable by 12h, peaked at 48h, and decreased by 96h (Figure 
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3.1F). As expected, levels of the pluripotency marker OCT4 decrease during 
differentiation (Figure 3.1F). Since RUNX1 protein is functionally organized in 
punctate nuclear foci (Zeng et al., 1998, 1997), we investigated its localization 
using immunofluorescence (IF) microscopy (Figure 3.1G). Undifferentiated 
hESCs were devoid of RUNX1 protein, but robust nuclear staining was detected 
in >90% of cells by 48h, which corroborates the RNA expression and FISH 
results. Taken together, these findings demonstrate that RUNX1 upregulation is 
specific for early differentiation towards mesendodermal lineages. 
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Figure 3.1. RUNX1 is transiently upregulated during early differentiation of human embryonic stem cells (hESCs) to mesendodermal lineages. (A) Diagram of gene expression profile of early mesendodermal differentiation of hESCs. (B) Relative transcript levels of select transcription factors, including the RUNX family, during early mesendodermal differentiation of hESCs. Graph represents mean±SEM from three independent experiments with a technical replicate each (N=6). (C) Relative levels of the RUNX1 isoforms in both the female (H9) and male (H1) hESCs with a schematic of different RUNX1 transcript isoforms. Graph represents mean±SEM from three independent experiments with a technical replicate each (N=6). (D) Relative levels of total RUNX1 transcript during directed differentiation to the three germ layers. No RUNX1 transcript was detected during ectoderm differentiation. Data represents the mean±SEM for three independent experiments with a technical replicate each (N=6). (E) Representative RNA FISH images showing RUNX1 RNA (red) at time 
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points indicated. Nuclei are stained with DAPI (blue). All images taken at 63X magnification. (F) Representative Western blot showing the transient increase in levels of RUNX1, and the decrease in OCT3/4 in the H1 and H9 hESCs during a mesendoderm differentiation time course with CDK2 used as the loading control. (G) Representative immunofluorescence images showing RUNX1 (green) nuclear staining at the time points indicated. Nuclei are stained with DAPI (blue). All images taken at 63X magnification. 
 
3.3.2 RUNX1 Regulates Cell Motility and EMT in Differentiating hESCs  
 To determine the functional role of RUNX1, we performed global gene 
expression profiling during early mesendodermal differentiation of hESCs in 
which RUNX1 had been depleted (Figure 3.2A). Knockdown of RUNX1 was 
confirmed by Western blot (Figure 3.2B), and microarray analysis was performed 
on total cellular RNA from uninfected, non-silencing (shNS), and RUNX1 
depleted (shRUNX1) hESCs at four time points (0h, 8h, 24h, 72h) (Figure 3.2A). 
Reproducibility of gene expression datasets from three independent experiments 
was demonstrated by principal component analysis, which shows the 
undifferentiated and differentiated hESC samples in distinct clusters. As 
differentiation progresses, shRUNX1 samples separate away from the control 
samples (uninfected and shNS) indicating that the depletion of RUNX1 has an 
effect on the differentiation, though the effect may be subtle (Figure 3.2A). 
Bioinformatics analyses determined that the non-silencing shRNA had very little 
effect on the differentiation time course. Upon RUNX1 knockdown, only a small 
number of genes were significantly changed (1.5-fold change with a p value ≤ 
0.05 and FDR p value ≤ 0.05) by 8h of differentiation (31). The number of genes 
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that were changed continued to increase by 24h (334) and 72h (435) (Figure 
3.2C). These observations indicate that the depletion of RUNX1 affects gene 
expression, and suggest a functional role for RUNX1 in early hESC 
differentiation. 
 We investigated which biological processes were altered by RUNX1 
knockdown during mesendodermal differentiation. Functional grouping of Gene 
Ontology (GO) annotations showed that three biological processes were 
potentially affected: regulation of endothelial cell proliferation, smooth muscle cell 
migration and cell adhesion (Figure 3.2D).  We experimentally addressed 
contributions of RUNX1 in the regulation of these processes. Proliferation was 
assessed by measuring growth curves of pluripotent or differentiating uninfected, 
shNS, or shRUNX1 hESCs (Figure 3.2E). RUNX1 depletion had no net effect on 
proliferation when compared with the two controls. This observation was further 
confirmed by measuring active DNA synthesis using BrdU incorporation (Figure 
3.2F), which showed no effect of RUNX1 knockdown on the percentage of BrdU 
positive cells in pluripotent or differentiating hESCs. 
 The effect of RUNX1 on the migration of differentiating hESCs was examined 
by scratch closure assays (Figure 3.2G and 3.2H). The extent of scratch closure 
was measured 18h after scratch initiation (Figure 3.2G). Uninfected and shRNA 
control cells achieved ~70% closure, while the shRUNX1 cells achieved only 
~40% closure (Figure 3.2H), indicating impaired migration upon RUNX1 
depletion. Taken together with the lack of RUNX1 effect on proliferation, these 
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findings establish a role for RUNX1 in regulating migration during early 
mesendodermal differentiation. 
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Figure 3.2. Knockdown of RUNX1 impairs the migration ability, but not the proliferation rate, of hESCs during mesendoderm differentiation. (A) Principal Component Analysis (PCA) of the time points, replicates, and treatments for mesendodermal differentiation of hESCs from transcriptome 
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profiling. Four time points (Undifferentiated (0h) [red], 8 hours (8h) [purple], 1 day (24h) [blue], and 3 days (72h) [green]) (n=3 replicates from independent experiments) were analyzed by microarray analysis under three different treatments (Uninfected (squares), Non-Silencing infected (triangles), and shRUNX1 (circles)). (B) Representative Western blot comparing the levels of RUNX1 in hESCs treated either with non-silencing shRNA or RUNX1 shRNA differentiating to mesendoderm, confirming that RUNX1 is knocked down in shRUNX1 hESCs.  (C) Venn diagram of the number of gene with expression changes greater than 1.5 fold, and p value and FDR p values < 0.05, at each differentiation time point under shRUNX1 treatment as compared to non-silencing infected hESCs. The total number of genes changed at each time point is in brackets. (D) ClueGO analysis of genes with significant expression changes reveals three biological processes that might effected by RUNX1 knockdown. The pie represents the total genes that were grouped into all three biological process, and each slice represents the percentage of the total genes grouped to each biological process. (E) Growth curves for hESCs either uninfected(blue), non-silencing infected (red), or with shRUNX1 (green) under pluripotent and mesendoderm differentiation conditions. Line graph represents mean±SEM from three independent experiments with a technical replicate each (N=6). No statistically significant differences were found (*, p<0.05). (F) Percent of cells staining positive for BrdU with a 30-minute pulse of labeling. Quantification of BrdU+ cells was performed using blind scoring in duplicate of 200 cells from immunofluorescent images, data represents mean±SEM from three independent experiments. No statistically significant differences were found (*, p<0.05). (G) Representative phase contrast images from a scratch closure assay. Cells were plated, differentiated for 48h, after 46h of differentiation cells were treated with Mitomycin C (to inhibit proliferation) and then a scratch was made. Closure was measured 18h later. All phase contrast images were taken at 10X magnification. (H) Percentage of scratch closure for hESCs uninfected, non-silencing infected, and infected with shRUNX1, as quantitated by Image J plugin. Ten scratches were measured for each condition, and data is represented as mean±SD, (*, p<0.001).   Consistent with these results, GO term analysis using DAVID revealed that 
knockdown of RUNX1 upregulated genes involved in cell-cell adhesion and 
junction interactions (Figure 3.3A).  Additionally, many of the top genes that are 
increased upon RUNX1 depletion during differentiation are associated with an 
epithelial-like phenotype (Figure 3.3B). These findings led us to experimentally 
test whether the epithelial to mesenchymal transition (EMT) was affected by loss 
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of RUNX1. We evaluated the expression of several epithelial (CDH1/E-Cadherin, 
OCLN, and CLD7) and mesenchymal (VIM, TWIST1, ZEB2, SNAI1, SNAI2, and 
CD44) marker genes across early mesendodermal differentiation in either shNS 
or shRUNX1 hESCs (Figure 3.4). A typical profile of cells undergoing EMT is 
observed in shNS hESCs, where all epithelial markers decreased and all 
mesenchymal markers increased during differentiation (Figure 3.4, light gray 
bars). However, in the absence of RUNX1, the epithelial markers decreased 
initially but were restored to undifferentiated levels by 72h (Figure 3.4, black 
bars). In contrast, the majority of mesenchymal markers were unaffected with the 
exception of ZEB2, which was not induced (Figure 3.4, black bars). Collectively 
these findings show that RUNX1 contributes modestly to regulation of a 
physiological EMT that occurs during early mesendodermal differentiation. 
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Figure 3.3. GO Term Analysis. (A) Using DAVID (version 6.7) for GO term analysis the top terms upregulated are involved in cell-cell adhesion and junction interactions. (B) A majority of the top upregulated genes are directly related to maintaining an epithelial phenotype.   
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Figure 3.4. Genes that regulate the epithelial to mesenchymal transition (EMT) are effected by RUNX1 knockdown. During mesendoderm differentiation of hESCs the levels of multiple effectors of EMT (epithelial associated [CDH1, OCLN, and CLD7] and mesenchymal associated [VIM, TWIST1, ZEB2, SNAI1, SNAI2, and CD44]) were measured by qRT-PCR under treatment by non-silencing infection, or shRUNX1. During the control (Non-Silencing) differentiation epithelial marker expression decreases and mesenchymal gene expression increases. However, with shRUNX1 treatment, the epithelial marker genes fail to be suppressed and ZEB2 is not induced. Data shown as mean±SEM from three independent experiments with a technical replicate each (N=6). P values were determined by Student’s t tests with Welch’s correction between non-silencing infected and shRUNX1 treatment at each corresponding time point (*, p < 0.0001).  
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3.3.3 RUNX1 Depletion Inhibits TGFβ2 Signaling  
 Because EMT is a complex process regulated by multiple signaling pathways 
(Derynck et al., 2014; Zhang et al., 2016), we performed signaling pathway 
analysis on annotated genes that changed significantly upon RUNX1 depletion 
(Figure 3.5A, and Table 3.3). Distinct pathways were activated by RUNX1 
knockdown at each time point, although no single pathway was activated at all 
time points. Conversely, the TGFβ pathway was the most inhibited across the 
differentiation time course (Figure 3.5A, and Table 3.3), suggesting that RUNX1 
activates TGFβ signaling during mesendodermal differentiation. 
 To directly investigate how RUNX1 regulates the TGFβ signaling pathway, we 
examined expression of the TGFβ ligands upon RUNX1 depletion (Figure 3.5B). 
TGFβ1 and TGFβ2 exhibited sequential and significant upregulation (>15 fold) 
during hESC differentiation, while TGFβ3, which is expressed at relatively low 
levels, remained unchanged. Importantly, only TGFβ2 expression was 
significantly affected by RUNX1 depletion (Figure 3.5B). We also found that both 
TGFβ1 and TGFβ2, but not TGFβ3, promoters contain RUNX1 consensus sites 
within 1 kb of the transcription start site. We tested whether RUNX1 binds to the 
TGFβ promoters using ChIP-qPCR (Figure 3.5C). Our results show that RUNX1 
selectively occupies the TGFβ2, but not the TGFβ1, promoter (Figure 3.5C), 
which is consistent with the effect of RUNX1 depletion on TGFβ2 expression 
(Figure 3.5B). As expected, RUNX1 occupied its own promoter, which was 
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included as a positive control (Knezevic et al., 2011). These results show that 
RUNX1 selectively occupies and regulates expression of the TGFβ2 gene. 
  We next examined whether downstream effectors of the canonical TGFβ2 
pathway were changed in the absence of RUNX1. Western blot analysis was 
carried out for both phospho- and total SMAD2 during mesendodermal 
differentiation (Figure 3.5D and Figure 3.6). In the control (non-silencing) time 
course, there was an increase in phospho-SMAD2 at 8h and 24h that decreased 
by 72h relative to total SMAD2 (Figure 3.5D, 3.6A, and 3.6B). This increase 
coincides with the expression of TGFβ1 and TGFβ2 ligands (Figures 3.5B, 3.5D 
and 3.6). Quantitation of the ratio of phospho- to total SMAD2 revealed a 
decrease at 24h and 72h upon RUNX1 knockdown (Figures 3.5D, 3.5E, and 
3.6B). Together, these findings show that RUNX1 is an upstream activator of 
TGFβ2 signaling during early mesendodermal differentiation. 
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Figure 3.5. Knockdown of RUNX1 inhibits the TGFβ signaling pathway, specifically through TGFβ2. (A) Top signaling pathways inhibited by RUNX1 knockdown as determined by Ingenuity Pathway analysis. (B) Relative expression of the three TGFβ ligands under non-silencing and shRUNX1 treatment by RT-qPCR. Data represented as mean±SEM from three independent experiments with a technical replicate each and a p value determined by T-test (*, p < 0.05). (C) ChIP-qPCR analysis for RUNX1 binding sites in the promoters of the TGFβ1, TGFβ2, and RUNX1 promoters. Experiments were carried out at the peak of RUNX1 protein expression at 48h of differentiation. Data represented as mean±SEM of fold enrichment from four independent experiments with a p value determined by T-test comparing specific signaling to signal obtained from the IgG control (*, p < 0.05). (D) Representative Western blot showing a decrease in levels of pSMAD2 at 24h and 72h, with an increase in total SMAD2 levels with shRUNX1 treatment during mesendoderm differentiation. (E) Quantitation of Western blots from three independent experiments. Data is represented as the mean±SEM of the ratio of pSMAD2 over total SMAD2, and though not statistically significant, there is a decrease in the ratio of pSMAD2 to total SMAD2 at 24h and 72h of differentiation.  
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 Figure 3.6. Further Analysis of pSMAD/SMAD2 Western Blot. (A)Representative Western blot showing a decrease in levels of pSMAD2 at 24h and 72h, with an increase in total SMAD2 levels with shRUNX1 treatment during mesendoderm differentiation. Loading controls of GAPDH and CDK2 are included. (B) Quantitation of Western blots from three independent experiments. Data is represented as the mean±SEM of the ratio of pSMAD2 over total SMAD, both normalized using the loading control CDK2. Normalizing to the loading control does not affect the overall result, as there is still a decrease in the ratio of pSMAD to total SMAD at 24h and 72h of differentiation. (C) Coomassie stained gel for Western blot showing no gross total difference in protein loading.  
3.3.4 TGFβ2 Rescues Impaired Cell Motility and Epithelial Gene Expression 
Caused by RUNX1 Depletion 
 The TGFβ pathway is known to regulate cell migration and adhesion (Xu et 
al., 2009).  Our findings reveal that RUNX1 affects cell motility (Figure 3.2G) and 
specifically regulates TGFβ2 expression (Figure 3.5B). We directly tested 
whether there is a connection between the defect in motility and EMT gene 
expression resulting from RUNX1 depletion and TGFβ2 signaling. Scratch 
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closure assays were performed to determine whether the effect of RUNX1 
depletion on hESC migration can be rescued by TGFβ2 (Figure 3.7). We found 
that addition of TGFβ2 significantly increased the scratch closure of the 
shRUNX1 hESCs from ~40% to ~60%; TGFβ1, which was included as a control, 
had no effect (Figure 3.7B). These findings are consistent with our discovery that 
RUNX1 occupies and transcriptionally activates the TGFβ2 gene (Figure 3.5B 
and 3.5C), and establish that RUNX1 regulation of hESC migration is mediated 
through TGFβ2. 
 TGFβ signaling can regulate EMT and the associated changes in cell 
adhesion and migration (Nieto, 2013; Thiery et al., 2009). Because RUNX1 
knockdown inhibits TGFβ signaling (Figure 3.5), we evaluated whether 
supplementation of the shRUNX1 cultures with exogenous TGFβ1 or TGFβ2 
could rescue the altered expression of EMT genes (Figure 3.7C). While TGFβ2 
caused significant repression of the epithelial markers to levels similar to those in 
shNS hESCs, TGFβ1 was unable to repress most of these genes (Figure 3.7C). 
TGFβ2 failed to induce expression of ZEB2, the only mesenchymal marker that 
was not upregulated during differentiation of shRUNX1 hESCs, suggesting that 
the effect of TGFβ2 is primarily epithelial (Figure 3.7C). These findings indicate 
that knockdown of RUNX1 alleviates repression of epithelial genes (Figure 3.4), 
and addition of TGFβ2 decreases the expression of these epithelial genes 
(Figure 3.7C). Taken together, our results show that the selective and transient 
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RUNX1 expression during early mesendodermal differentiation of hESCs 
regulates cell motility and EMT gene expression through TGFβ2. 
 
 
 
92  
 
Figure 3.7. Defects in cell motility and EMT gene expression caused by RUNX1 depletion are rescued by reintroduction of TGFβ2, but not TGFβ1. (A) Representative phase contrast images from a scratch closure assay. Assays were carried out as in Figure 2G, with the addition of TGFβ ligand. All phase contrast images were taken at 10X magnification. (B) Percentage of scratch closure for hESCs with non-silencing infection, and shRUNX1 infection, as wells as shRUNX1 cells supplemented with exogenous TGFβ1 or TGFβ2, as 
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quantitated by Image J plugin. Ten scratches were measured for each condition, and data is represented as mean±SD, (***, p<0.001). (C) The expression of the four genes that were found to be affected by RUNX1 knockdown (CDH1, OCLN, CLD7, and ZEB2) with Non-Silencing, shRUNX1, shRUNX1+TGFβ2, and shRUNX1+TGFβ1 over a mesendoderm differentiation time course. Data shown as mean±SEM from three independent experiments with a technical replicate each (N=6). P values were determined by t-test between shRUNX1 and either shRUNX1 cells supplemented with TGFβ2, or TGFβ1 (#, p < 0.0001). 
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3.4 Discussion for Chapter III 
 In this chapter, we discovered unexpected, transient expression of the 
phenotypic transcription factor RUNX1 during early mesendodermal 
differentiation of hESCs, which suggested that RUNX1 contributes to 
differentiation in addition to its established role in hematopoietic lineage identity. 
Our findings showed that RUNX1 regulates cell motility and gene expression 
during mesendodermal differentiation specifically through TGFβ2 signaling 
(Figure 3.8). These results suggest a novel role for RUNX1 in early development. 
 
Figure 3.8 Graphical Summary of Chapter III. 
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 The discovery of a burst of RUNX1 expression was both selective and 
specific because none of the other examined phenotypic transcription factors 
showed increased expression. RUNX1 expression from the distal P1 promoter is 
linked with the emergence of definitive hematopoietic stem cells (Chen et al., 
2009; Lacaud et al., 2002; Okuda et al., 1996), but little work has been done on 
the role of transcripts from the more ubiquitous proximal P2 promoter (Challen 
and Goodell, 2010; Fujita et al., 2001; Sroczynska et al., 2009). In this study, the 
RUNX1 transcript that we found during early mesendodermal differentiation is the 
RUNX1b isoform from the P2 promoter. Interestingly, the RUNX1 P2 promoter 
from which the RUNX1b transcript originates is poised for expression, being 
bivalently marked with H3K27me3 and H3K4me3, in undifferentiated hESC, while 
the P1 promoter is not (Figure 1.2) (Mikkelsen et al., 2007). Additionally, the 
transcripts from the two promoters are translated through different primary 
mechanisms with the P1 transcript translated through a cap-mediated 
mechanism, and the P2 transcripts translated though an IRES mediated 
mechanism (Pozner et al., 2000), which is often used in times of cellular stress, 
mitosis, and during differentiation (Komar and Hatzoglou, 2011). This supports 
the idea that the RUNX1 expression from the P2 promoter has evolved 
specifically to be expressed early under differentiating conditions, indicating it 
could have an important role in early development.  
 Our discovery of a rapid, substantial increase in RUNX1 expression early in 
differentiation to mesendoderm suggests a potential role for RUNX1 that is 
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unrelated to hematopoiesis. We provide evidence that RUNX1 has a role in early 
mesendodermal differentiation of hESCs through regulation of cell migration and 
adhesion, as indicated by impairment of these processes upon RUNX1 depletion. 
These findings are consistent with the emerging role of RUNX1 in controlling cell 
motility and migration in other biological systems. We have previously shown that 
RUNX1 depletion in breast cancer cells results in a decreased migration and 
invasion phenotype (Browne et al., 2015); similar results were found in ovarian 
cancer cells (Keita et al., 2013). Likewise, RUNX1b is responsible for inducing a 
cell adhesion and migration program prior to release of mouse hematopoietic 
stem cells from hemogenic endothelium (Lie-A-Ling et al., 2014).  
 One notable result was that upon RUNX1 depletion there was decrease in 
cell motility and a de-repression of epithelial markers, which suggests that there 
is a requirement for RUNX1 to produce proper EMT. However, when the 
morphology of the differentiating cells was examined, there were not any 
differences between control and knockdown cells, which is unexpected because 
of the connection between EMT and cell morphological changes. Interestingly, 
one study has shown that the cell morphological changes associated with EMT 
precede down-regulation of E-Cadherin, and forced expression of E-Cadherin did 
not affect cell morphology (Maeda et al., 2005). This study indicates that it is 
possible that the deregulation of the epithelial markers could not have an effect 
on cell morphology, while still influencing cell adhesion or migration in the EMT 
process. 
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 Gene expression profiling of early mesendodermal differentiation revealed 
that RUNX1 regulates TGFβ signaling, which has known roles in maintenance of 
pluripotency of hESCs (James et al., 2005; Wei et al., 2005), differentiation (Itoh 
et al., 2014; Watabe and Miyazono, 2009) and EMT (Xu et al., 2009).  The 
inhibition of motility and de-repression of epithelial genes observed upon RUNX1 
depletion indicates that RUNX1 is upstream of the TGFβ pathway. Moreover, we 
found that RUNX1 specifically occupies and regulates the expression of the 
TGFβ2 gene, which encodes one of the three TGFβ ligands. Though the TGFβ 
ligands share greater than 70% homology (Kingsley, 1994), studies of knockout 
mice show non-overlapping phenotypes, indicating that each ligand has specific 
functions in development (Sanford et al., 1997). TGFβ2 knockout mice have 
cardiac, lung, craniofacial, limb, spinal column, eye, inner ear and urogenital 
defects (Sanford et al., 1997), whereas  the TGFβ1 mice exhibit an autoimmune-
like inflammatory disease or embryonic lethality due to defective yolk sac 
hematopoiesis and vasculogenesis depending on the genetic background 
(Dickson et al., 1995; Kulkarni et al., 1993; Shull et al., 1992). Consistent with the 
results from these mouse models, we found a specific requirement for TGFβ2, 
but not TGFβ1, to rescue the phenotype of RUNX1 depletion.  
 In addition to a decrease in TGFβ2 ligand expression upon RUNX1 depletion, 
we also found a decrease in phosphorylation of the downstream effector SMAD2. 
SMAD2 is required for proper gastrulation, as well as primitive 
streak/mesendoderm and mesoderm formation, with SMAD2 knockout being 
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embryonic lethal before E8.5 (Nomura and Li, 1998; Weinstein et al., 1998). This 
is consistent with the idea that RUNX1 has a role in mesendodermal regulation 
upstream of TGFβ2-SMAD2 signaling. 
 One result that did not fit well into our model of RUNX1 regulating TGFβ2 
signaling, motility, and epithelial marker gene expression was that when RUNX1 
was depleted, the expression of the mesenchymal associated transcription factor 
ZEB2 was not induced. ZEB2 was the only mesenchymal associated gene 
whose expression was found to be altered by RUNX1 knockdown, as the primary 
effect of RUNX1 depletion was on epithelial marker genes. ZEB2 is an important 
regulator of EMT, responsible for down-regulating epithelial markers (Kalluri and 
Weinberg, 2009; Vandewalle et al., 2005). One hypothesis was that the effect on 
epithelial marker genes was mediated through ZEB2. ZEB2 expression was not 
rescued by introduction of exogenous TGFβ2, and was only very slightly induced 
upon exposure to TGFβ1, while the expression of epithelial genes was re-
repressed to levels similar to what is observed in control cells. This suggests that 
the effect on epithelial gene expression was not mediated through ZEB2. 
However, while introduction of exogenous TGFβ2 did not rescue RNA expression 
levels, there is the possibility that TGFβ2 post transcriptionally increased the 
levels of ZEB2, which was then responsible for decreasing the level of epithelial 
marker genes.  
 Interestingly, when ZEB2 is conditionally knocked out in mice, the phenotype 
was noted as similar to the RUNX1 knockout mouse with embryonic lethality by 
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E12.5, however ZEB2 is not necessary for hematopoietic stem cell formation, but 
rather to establish hematopoietic lineage differentiation potential (Goossens et 
al., 2011). This could indicate that ZEB2 is a downstream target of RUNX1. We 
tested whether there was direct binding of RUNX1 to the ZEB2 promoter, and did 
not find any, though this does not rule out that RUNX1 regulates ZEB2 
expression through an enhancer or other distal site.  
 Were this work to be continued, one thing that could be investigated in more 
detail is the effect of RUNX1 depletion on TGFβ2 signaling. The current work has 
been limited to examining the transcript levels of the TGFβ ligands and the 
phosphorylation levels of SMAD2. However, there is a long process between 
transcription of a ligand and presentation of active ligand to the cell surface 
receptor. Therefore, it might be informative to assay by ELISA the amount of 
active human and bovine (supplied in the media) TGFβ1 and TGFβ2 present in 
the media. This result might be more meaningful since it would measure ligands 
in the forms that can directly affect the cells and would eliminate the possibility 
that the transcriptional differences in ligand expression are nullified in either the 
translational processing or in the activation step.  
 In conclusion, our discovery of Runx1-mediated regulation of TGFβ2 signaling 
provides mechanistic insights into early mesendodermal differentiation. These 
results also establish RUNX1 as a selective and specific regulator of cell motility 
and EMT-associated gene expression. 
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CHAPTER IV. Discussion 
The overarching goal of this body of work was to examine some of the 
early mechanisms that control the development of a whole organism from a 
single cell. Using human embryonic stem cells (hESCs), which can recapitulate 
in vivo developmental events, we tested the hypothesis that key regulatory 
events take place at very early stages of human embryonic stem cell (hESC) 
differentiation that accommodate their ability to differentiate into specific lineages. 
The studies in this dissertation focused mainly on the regulation of differentiation 
to mesendodermal lineages. Of note, the progression of differentiation of hESC 
to mesendodermal lineages was very reproducible, which made obtaining 
consistent results possible. 
In Chapter II of this dissertation, we investigated mechanisms that connect 
alterations in the cell cycle to early lineage commitment. We discovered a cell 
cycle pause that occurred concurrently with an increase in expression of genes 
that regulate the G2/M transition, including WEE1, which when inhibited 
prevented this G2 pause. This pause was only observed during commitment to 
the endo- and mesodermal, but not ectodermal, lineages. WEE1 inhibition during 
meso- and endodermal differentiation selectively compromised differentiation to 
endoderm. Taken together these findings revealed a novel G2 cell cycle pause 
required for endodermal differentiation.  
In Chapter III of this dissertation, we examined whether phenotypic 
transcription factors have a role in very early differentiation to mesendodermal 
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lineages prior to their known role in establishing lineage identity.  We performed 
a screen of candidate transcription factors and found that RUNX1 is selectively 
and transiently up-regulated. In order to determine if RUNX1 has a role in early 
differentiation, we carried out transcriptome profiling and functional analyses 
upon RUNX1 depletion. These approaches established a role for RUNX1 in 
promoting cell motility and repressing several epithelial genes, which are 
required to complete the epithelial to mesenchymal transition during 
differentiation. Cell biological and biochemical assays revealed that RUNX1 
depletion inhibited TGFβ2 signaling. Both the decrease in motility and 
deregulated epithelial marker expression in the absence of RUNX1 were rescued 
by reintroduction of TGFβ2, but not TGFβ1. These findings identify novel roles for 
a RUNX1-TGFβ2 signaling axis during mesendodermal lineage commitment. 
Though both of the regulatory processes examined in this dissertation are 
active during the same period of early mesendodermal differentiation, there does 
not appear to be a direct connection between the two mechanisms. When the G2 
cell cycle pause caused by WEE1 was inhibited, it had no effect on RUNX1 
expression levels during differentiation to any lineage. The reverse situation is 
true as well; when RUNX1 was depleted in hESCs differentiated to 
mesendodermal lineages there was no effect on the cell cycle pause or net 
proliferation in general. It was important to show that RUNX1 depletion had no 
effect on the cell cycle profile or proliferation since previous studies have shown 
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RUNX1 can regulate cell cycle progress and proliferation in other systems 
(Bernardin and Friedman, 2002; Chimge et al., 2016; Friedman, 2009).  
One limitation of the studies in both chapters of this dissertation is that all 
the experiments focused on studying the downstream effects/effectors of the 
regulatory mechanism/regulator. An interesting direction for future research 
would be to try to figure out what was upstream of either WEE1 or RUNX1 in the 
regulatory pathway. It would be interesting to find out what was initiating these 
regulatory mechanisms as it could give insight into how their lineage specificity 
was determined/maintained. Unfortunately, there were no transcriptome profiling 
time points collected earlier than 8 hours of differentiation (by which time WEE1 
and RUNX1 had already been induced), as it was unexpected how early these 
regulatory mechanisms started. This data could give a clue as to what is being 
expressed earlier and possibly functioning as an inducer. However, having the 
transcriptome data would not necessarily be able to answer the question of what 
is inducting WEE1 or RUNX1, as there are many varieties of post-transcriptional 
mechanisms that could be involved. Additionally, if we were able to determine 
what was inducing the expression of WEE1 and/or RUNX1, this might also 
indicate what is responsible for the subsequent down regulation of these factors. 
This information is important because the “off” switch of a regulatory mechanism 
is as important as the “on” switch, since each early event is very tightly 
coordinated and timed with the other events necessary for proper development.
 We had hypothesized that RUNX1 was being induced by TGFβ1, as it has 
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been shown that TGFβ1 can induce RUNX expression (Jin et al., 2004; Klunker 
et al., 2009; Miyazono et al., 2004), that TGFβ1 is a regulator of EMT, and that 
TGFβ1 is already highly expressed by 8 hours of mesendodermal differentiation 
with an expression pattern that mirrors RUNX1 expression. However, since 
TGFβ1 is a key signal required to maintain pluripotency as well as promote 
differentiation, any alteration in TGFβ1 signaling altered multiple properties of the 
differentiation. Also, TGFβ1 is both expressed by the cell and contributed by the 
medium, making it technically challenging to alter the levels of TGFβ1 signaling. 
Therefore, connecting the expression of RUNX1 directly back to TGFβ1 was not 
possible from a technical perspective. 
A challenge associated with studying early mechanisms of differentiation 
is defining the lineages that develop. One reason that this is a challenge is that 
there are very few markers for lineages that are expressed within the first few 
days of differentiation. Many markers of early lineages were first discovered in 
studies of development in early mouse embryos, where in addition to marker 
expression, there is the advantage of three dimensional positioning to aid in cell 
type/lineage identification. In hESC culture, where there is no three dimensional 
positioning, many markers that have been put forward as being specific for a 
specific early cell type or lineage are not in fact very specific, and there are 
multiple conflicting reports as to what lineages are marked by certain genes. For 
example, GBX2 is listed in several papers as a marker of early ectoderm 
(Pazhanisamy, 2015; Vallier et al., 2009), but another paper reveals that GBX2 is 
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also expressed in early presomitic mesoderm (Carapuço et al., 2005). In Figure 
2.10, GBX2 was expressed during ectodermal differentiation, but there was also 
expression during mesodermal differentiation. This was initially unexpected 
based on GBX2 being considered a marker of ectoderm, but now is explainable 
after learning about the role of GBX2 in presomitic mesoderm.  
Additionally, when maintaining pluripotent stem cells, there is always a 
certain amount of heterogeneity in level of pluripotency, with spontaneous 
differentiation occurring as well, which can result in high levels of unexpected 
markers depending on the amount and type of spontaneous differentiation 
(Laslett et al., 2007; Nair et al., 2015). This could explain why there are levels of 
ectodermal markers observed late during differentiation toward the 
mesendodermal lineages, and why markers of other lineages are observed 
during lineage specific differentiation, since a certain percentage of cells had 
already begun to spontaneously differentiate to other lineages before 
differentiation had been induced. 
The discovery of these two novel regulatory mechanisms detailed in this 
dissertation indicate that there are many undiscovered regulatory mechanisms 
controlling early development and differentiation. If this research were to be 
continued there are several areas of investigation that may prove interesting. 
One interesting result from the analysis of the microarray data is that there is an 
enrichment of genes related to the positive regulation of smooth muscle and 
heart contraction among the genes that had increased expression during 
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mesendodermal differentiation. GO TERM analysis of genes that decreased 
upon depletion of RUNX1 revealed an enrichment in genes associated with 
smooth muscle and muscle contraction (Figure 3.3). It would be interesting to 
take the RUNX1 knockdown cells and perform directed differentiation toward the 
smooth muscle lineage and compare their lineage marker expression and ability 
to contract to that of control cells. This might provide evidence that early RUNX1 
expression has functional consequence on later differentiation events. 
A further study of interest would be to perform the same screen of 
candidate transcription factors or transcriptome profiling during very early 
differentiation to ectodermal lineages, as the present studies were performed 
during mesendodermal differentiation. This might reveal a novel role for an 
unexpected transcription factor in ectodermal differentiation.  
In conclusion, this dissertation has examined two separate regulatory 
mechanisms that act very early in hESC differentiation and accommodate 
differentiation into specific lineages. One of these mechanisms is a novel G2 cell 
cycle pause required for endodermal differentiation, the other is early RUNX1 
expression during mesendodermal differentiation that is necessary to properly 
regulate cell motility and EMT gene expression. The understanding of these 
processes has expanded our knowledge of the complex series of events that are 
required at every step of development to create the intricate creature that is a 
human being.  
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